



(86) Date de dépôt PCT/PCT Filing Date: 2000/08/24
(87) Date publication PCT/PCT Publication Date: 2001/03/01
(45) Date de délivrance/Issue Date: 2012/10/23
(85) Entrée phase nationale/National Entry: 2002/02/22
(86) N° demande PCT/PCT Application No.: DK 2000/000469
(87) N° publication PCT/PCT Publication No.: 2001/014535
(30) Priorité/Priority: 1999/08/24 (US60/150,488)

(51) Cl.Int./Int.Cl. *C12N 15/54* (2006.01),
A61K 31/7088 (2006.01), *A61K 38/45* (2006.01),
A61K 39/395 (2006.01), *A61K 48/00* (2006.01),
C07H 21/00 (2006.01), *C07K 16/40* (2006.01),
C12N 9/10 (2006.01), *C12P 19/18* (2006.01),
C12P 19/34 (2006.01), *C12Q 1/48* (2006.01),
C12Q 1/68 (2006.01), *C40B 30/08* (2006.01),
G01N 33/573 (2006.01), *A61K 38/00* (2006.01)

(72) Inventeurs/Inventors:
SCHWIEN TEK, TILO, DK;
CLAUSEN, HENRIK, DK

(73) Propriétaire/Owner:
GLYCOZYM APS, DK

(74) Agent: NORTON ROSE CANADA

(54) Titre : UDP-N-ACETYLGLUCOSAMINE: GALACTOSE- β 1,3-N-ACETYL GALACTOSAMINE- α -R/(GLCNAC - GALNAC) β 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GNT3

(54) Title: UDP-N-ACETYLGLUCOSAMINE: GALACTOSE- β 1,3-N-ACETYL GALACTOSAMINE- α -R/(GLCNAC TO GALNAC) β 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GNT3

(57) **Abrégé/Abstract:**

A novel gene defining a novel human UDP-GlcNAc: Gal β 1-3GlcNAc α β 1, 6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3, as well as cloning and expression vectors including such DNA. The enzyme C2GnT3 -active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3. Further, the invention discloses methods of obtaining 1,6-N-acetylglucosaminyl glycosylated saccharides, glycopeptides or glycoproteins by use of an enzymatically active C2GnT3 protein or fusion protein thereof or by using cells stably transfected with a vector including DNA encoding an enzymatically active C2GnT3 protein. Methods are disclosed for the identification of agents with the ability to inhibit or stimulate the biological activity of C2GnT3.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14535 A3(51) International Patent Classification⁷: C12N 9/10

(21) International Application Number: PCT/DK00/00469

(22) International Filing Date: 24 August 2000 (24.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/150,488 24 August 1999 (24.08.1999) US

(71) Applicants and

(72) Inventors: SCHWIENTEK, Tilo [DE/DK]; Sonnerupvej
69, DK-2700 Brønshøj (DK). CLAUSEN, Henrik
[DK/DK]; Norske Allé 2, DK-2840 Holte (DK).(74) Agent: HOFMAN-BANG A/S; Hans Bekkevolds Allé 7,
DK-2900 Hellerup (DK).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**Published:**

— With international search report.

(88) Date of publication of the international search report:
21 June 2001*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*(54) Title: UDP-N-ACETYLGLUCOSAMINE: GALACTOSE- β 1,3-N-ACETYLGLACTOSAMINE- α -R/(GlcNAc to GalNAc)
 β 1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3(57) Abstract: A novel gene defining a novel human UDP-GlcNAc: Gal β 1-3GAINAc α β 1, 6GlcNAc-transferase, termed C2GnT3, with unique enzymatic properties is disclosed. The invention discloses isolated DNA molecules and DNA constructs encoding C2GnT3, as well as cloning and expression vectors including such DNA. The enzyme C2GnT3 -active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of C2GnT3. Further, the invention discloses methods of obtaining 1,6-N-acetylglucosaminyl glycosylated saccharides, glycopeptides or glycoproteins by use of an enzymatically active C2GnT3 protein or fusion protein thereof or by using cells stably transfected with a vector including DNA encoding an enzymatically active C2GnT3 protein. Methods are disclosed for the identification of agents with the ability to inhibit or stimulate the biological activity of C2GnT3.

WO 01/14535 A3

UDP-N-Acetylglucosamine: Galactose- β 1,3-N-Acetyl-galactosamine- α -R / (GlcNAc to GalNAc) β 1,6-N-Acetylglucosaminyltransferase, C2GnT3

TECHNICAL FIELD

5 The present invention relates generally to the biosynthesis of glycans found as free oligosaccharides or covalently bound to proteins and glycolipids. In particular, this invention relates to a family of nucleic acids encoding UDP-N-acetylglucosamine: N-acetylgalactosamine-
10 β 1,6-N-acetylglucosaminyltransferases (Core- β 1,6-N-acetylglucosaminyltransferases), which add N-acetylglucosamine to the hydroxy group at C6 of 2-acetamido-2-deoxy-D-galactosamine (GalNAc) in O-glycans of the core 1 and the core 3 type thereby forming the core 2 and core 4 types.
15 Previously two members of this family have been identified and designated C2GnT1 and C2GnT2.

This invention is more particularly related to a gene encoding a third member of this family of O-glycan β 1,6-N-acetylglucosaminyltransferases, termed C2GnT3, probes to
20 the DNA encoding C2GnT3, DNA constructs comprising DNA encoding C2GnT3, recombinant plasmids and recombinant methods for producing C2GnT3, recombinant methods for stably transforming or transfecting cells for expression of C2GnT3, methods for identification of agents with the
25 ability to inhibit or stimulate C2GnT3 biological activity, and methods for identification of DNA polymorphism in patients. In the U.S. Provisional Patent Application No. 60/150,488 filed on August 24, 1999, from which the present application claims priority, this novel Core 2
30 β 6GlcNAc-transferase isoform was identified and designated C2GnTII. The designation C2GnTII has here been re-

placed by the designation C2GnT3 in accordance with its scientific publication (14).

BACKGROUND OF THE INVENTION

O-linked protein glycosylation involves an initiation stage in which a family of *N*-acetylgalactosaminyltransferases catalyzes the addition of *N*-acetylgalactosamine to Serine or Threonine residues (1). Further assembly of O-glycan chains involves several successive or alternative biosynthetic reactions: i) formation of simple mucin-type core 1 structures by UDP-Gal: GalNAc α -R β 1,3Gal-transferase activity; ii) conversion of core 1 to complex-type core 2 structures by UDP-GlcNAc: Gal β 1-3GalNAc α -R β 1,6GlcNAc-transferase activities; iii) direct formation of complex mucin-type core 3 by UDP-GlcNAc: GalNAc α β 1,3GlcNAc-transferase activities; and iv) conversion of core 3 to core 4 by UDP-GlcNAc: GlcNAc β 1-3GalNAc α -R β 1,6GlcNAc-transferase activity. The formation of β 1,6GlcNAc branches (reactions ii and iv) may be considered a key controlling event of O-linked protein glycosylation leading to structures produced upon differentiation and malignant transformation (2-6). For example, increased formation of GlcNAc β 1-6GalNAc branching in O-glycans has been demonstrated during T-cell activation, during the development of leukemia, and for immunodeficiencies like Wiskott-Aldrich syndrome and AIDS (7; 8). Core 2 branching may play a role in tumor progression and metastasis (9). In contrast, many carcinomas show changes from complex O-glycans found in normal cell types to immaturely processed simple mucin-type O-glycans such as T (Thomsen-Friedenreich antigen; Gal β 1-3GalNAc α 1-R), Tn (GalNAc α 1-R), and sialosyl-Tn (NeuAc α 2-6GalNAc α 1-R) (10). The molecular basis for this has been extensively studied in breast cancer, where it was shown that specific downregulation of a core 2 β 6GlcNAc-transferase was

responsible for the observed lack of complex type O-glycans on the mucin MUC1 (6). O-glycan core assembly may therefore be controlled by inverse changes in the expression level of Core- β 1,6-N-acetylglucosaminyltransferases and the sialyltransferases forming sialyl-T and sialyl-Tn.

Interestingly, the metastatic potential of tumors has been correlated with increased expression of core 2 β 6GlcNAc-transferase activity (5). The increase in core 2 β 6GlcNAc-transferase activity was associated with increased levels of poly N-acetylactosamine chains carrying sialyl-Le^x, which may contribute to tumor metastasis by altering selectin-mediated adhesion (4; 11). The control of O-glycan core assembly is regulated by the expression of key enzyme activities; however, epigenetic factors including posttranslational modification, topology, or competition for substrates may also play a role in this process (11).

Changes in surface carbohydrates of T-cells have been identified during development and activation. O-glycan branches of the core 2 type are restricted to immature thymocytes of the thymal cortex but are no longer exposed on the surface of mature medullary thymocytes (17). Core 2 structures on T-cell surface proteins are ligands for the S-type lectin galectin-1, which participates in thymocyte - thymic epithelia interaction (18). The elimination of Core 2 structures from the thymocyte cell surface was found to be essential for controlled apoptosis mediated by galectin-1 (19).

Core 2 β 6GlcNAc-transferase activity is carried out by more than one enzyme isoform. The first Core 2 β 6GlcNAc-transferase isoform was initially identified as a critical enzyme in blood cell development and differentiation

and designated leukocyte form or L-Form (C2GnT-L) (12). The gene encoding C2GnT-L has been cloned by expression cloning from a cDNA library of the human promyelocytic leukemia cell line HL-60 (13). This gene has now been re-
5 named as C2GnT1 (14). Using the C2GnT1 sequence as a probe for BLAST analysis of the human expressed sequence tag database, a homologous gene encoding a second Core 2 β 6GlcNAc-transferase isoform has been identified and designated C2/4GnT (15) and C2GnT-M (16). This gene has now
10 been renamed as C2GnT2 (14).

C2GnT1 was predicted to control synthesis of core 2 selectin ligands in leukocytes and lymphoid tissues, however, mice deficient in C2GnT1 exhibited only partial reduction in selectin ligand production and no significant
15 changes in lymphocyte homing properties (Ellies, L. G., et al. 1998, Immunity 9: 881-890). One possible explanation for these results would be the expression of additional Core 2 β 6GlcNAc-transferases. C2GnT2 does not appear to be a candidate, as its expression pattern is re-
20 stricted to mucous secreting organs (15, 16).

Consequently, there exists a need in the art for detecting as yet unidentified UDP-N-acetylglucosamine: Galactose- β 1,3-N-acetylgalactosamine- α -R (GlcNAc to GalNAc) β 1-6 N-acetylglucosaminyltransferases and identifying the
25 primary structures of the genes encoding such enzymes. The present invention meets this need, and further presents other related advantages.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids encoding human UDP-N-acetylglucosamine: N-acetylgalactosamine β 1,6 N-acetylglucosaminyltransferase 3 (C2GnT3), in-
30

cluding cDNA and genomic DNA. C2GnT3 has acceptor substrate specificities comparable to C2GnT1 (14). The complete nucleotide sequence encoding C2GnT3 is set forth in SEQ ID NO: 1 and in Figure 1.

- 5 Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. Any and all such nucleic acid variations are within the scope of the invention. DNA sequence polymorphisms may also occur which lead to changes in the amino
10 acid sequence of a C2GnT3 polypeptide. These amino acid polymorphisms are also within the scope of the present invention. In addition, species variations i.e. variations in nucleotide sequence naturally occurring among different species, are within the scope of the invention.
- 15 Among Core 2 β 6GlcNAc-transferases, C2GnT3 appears to be the dominant isoform in thymus (14). Thus, C2GnT3 is likely to have important functions during thymocyte development as well as T-cell maturation and homing (14). The identification of agents with the ability to inhibit
20 or stimulate C2GnT3 enzymatic activity therefore has the potential for both diagnostic and therapeutic purposes of related diseases.

Access to the gene encoding C2GnT3 allows production of a glycosyltransferase for use in formation of core 2-based
25 O-glycan modifications on oligosaccharides, glycoproteins and glycosphingolipids. This enzyme can be used, for example, in pharmaceutical or other commercial applications that require synthetic addition of core 2-based O-glycans to these or other substrates, in order to produce
30 appropriately glycosylated glycoconjugates having particular enzymatic, immunogenic, or other biological and/or physical properties.

In one aspect, the invention encompasses isolated nucleic acids comprising the nucleotide sequence of nucleotides 1-1362 as set forth in Figure 1 or sequence-conservative or function-conservative variants thereof. Also provided are
5 isolated nucleic acids hybridizable with nucleic acids having the sequence as set forth in Figure 1 or fragments thereof or sequence-conservative or function-conservative variants thereof; preferably, the nucleic acids are hybridizable with C2GnT3 sequences under conditions of intermediate stringency, and, most preferably, under conditions of high stringency. In one embodiment, the DNA sequence encodes the amino acid sequence shown in Figure 1, from methionine (amino acid no. 1) to serine (amino acid no. 453). In another embodiment, the DNA sequence encodes
10 an amino acid sequence comprising a sequence from proline (no. 39) to serine (no. 453) of the amino acid sequence set forth in Figure 1.

In a related aspect, the invention provides nucleic acid vectors comprising C2GnT3 DNA sequences, including but not
20 limited to those vectors in which the C2GnT3 DNA sequence is operably linked to a transcriptional regulatory element, with or without a polyadenylation sequence. Cells comprising these vectors are also provided, including without limitation transiently and stably expressing
25 cells. Viruses, including bacteriophages, comprising C2GnT3-derived DNA sequences are also provided. The invention also encompasses methods for producing C2GnT3 polypeptides. Cell-based methods include without limitation those comprising: introducing into a host cell an isolated
30 DNA molecule encoding C2GnT3, or a DNA construct comprising a DNA sequence encoding C2GnT3; growing the host cell under conditions suitable for C2GnT3 expression; and isolating C2GnT3 produced by the host cell. A method for generating a host cell with *de novo* stable expression of

C2GnT3 comprises: introducing into a host cell an isolated DNA molecule encoding C2GnT3 or an enzymatically active fragment thereof (such as, for example, a polypeptide comprising amino acids 39-453 of the sequence set forth Figure 1), or a DNA construct comprising a DNA sequence encoding C2GnT3 or an enzymatically active fragment thereof; selecting and growing host cells in an appropriate medium; and identifying stably transfected cells expressing C2GnT3. The stably transfected cells may be used for the production of C2GnT3 enzyme for use as a catalyst and for recombinant production of peptides or proteins with appropriate glycosylation. For example, eukaryotic cells, whether normal or diseased cells, having their glycosylation pattern modified by stable transfection as above, or components of such cells, may be used to deliver specific glycoforms of glycopeptides and glycoproteins, such as, for example, as immunogens for vaccination.

In yet another aspect, the invention provides isolated C2GnT3 polypeptides, including without limitation polypeptides having the sequence set forth in Figure 1, polypeptides having the sequence of amino acids 39-453 as set forth in Figure 1, and a fusion polypeptide consisting of at least amino acids 39-453 as set forth in Figure 1 fused in frame to a second sequence, which may be any sequence that is compatible with retention of C2GnT3 enzymatic activity in the fusion polypeptide. Suitable second sequences include without limitation those comprising an affinity ligand or a reactive group.

In a related aspect, methods are disclosed for the identification of agents with the ability to inhibit or stimulate the enzymatic activity of C2GnT3. Assays utilizing C2GnT3 to screen for potential inhibitors or stimulators thereof are encompassed by the invention. Furthermore,

methods of using C2GnT3 in the structure-based design of inhibitors or stimulators thereof are also an aspect of the invention. Such a design would comprise the steps of determining the three-dimensional structure of the C2GnT3 polypeptide, analyzing the three-dimensional structure for the likely binding sites of donor and / or acceptor substrates, synthesis of a molecule that incorporates a predictive reactive site, and determining the inhibiting or stimulating activity of the molecule.

10 In another aspect of the present invention, methods are disclosed for screening for mutations in the coding region of the C2GnT3 gene using genomic DNA isolated from, e.g., blood cells of patients. In one embodiment, the method comprises: isolation of DNA from a patient; PCR amplification of the coding exon; DNA sequencing of amplified exon DNA fragments and establishing therefrom potential structural defects of the C2GnT3 gene associated with disease.

In accordance with an aspect of the invention there is provided a method of, and products for (i.e. kits), diagnosing and monitoring conditions mediated by C2GnT3 by determining the presence of nucleic acid molecules and polypeptides of the invention.

Still further the invention provides a method for evaluating a test compound for its ability to modulate the biological activity of a C2GnT3 polypeptide of the invention. For example, a substance that inhibits or enhances the catalytic activity of a C2GnT3 polypeptide may be evaluated. "Modulate" refers to a change or an alteration in the biological activity of a polypeptide of the invention. Modulation may be an increase or a decrease in activity, a change in characteristics, or any other change in the biological, functional, or immunological properties of the polypeptide.

Compounds which modulate the biological activity of a polypeptide of the invention may also be identified using the methods of the invention by comparing the pattern and level of expression of a nucleic acid molecule or polypeptide of the invention in biological samples, tissues and cells, in the presence, and in the absence of the compounds.

In an embodiment of the invention a method is provided for screening a compound for effectiveness as an antagonist of a polypeptide of the invention, comprising the steps of a) contacting a sample containing said polypeptide with a compound, under conditions wherein antagonist activity of said polypeptide can be detected, and b) detecting antagonist activity in the sample.

Methods are also contemplated that identify compounds or substances (e.g. polypeptides), which interact with C2GnT3 nucleic acid regulatory sequences (e.g. promoter sequences, enhancer sequences, negative modulator sequences).

The nucleic acids, polypeptides, and substances and compounds identified using the methods of the invention, may be used to modulate the biological activity of a C2GnT3 polypeptide of the invention, and they may be used in the treatment of conditions mediated by C2GnT3 such as proliferative diseases including cancer, and thymus-related disorders. Accordingly, the nucleic acids, polypeptides, substances and compounds may be formulated into compositions for administration to individuals suffering from one or more of these conditions. Therefore, the present invention also relates to a composition comprising one or more of a polypeptide, nucleic acid molecule, or substance or compound identified using the methods of the invention, and a pharmaceutically acceptable carrier,

excipient or diluent. A method for treating or preventing these conditions is also provided comprising administering to a patient in need thereof, a composition of the invention.

5 The present invention in another aspect provides means necessary for production of gene-based therapies directed at the thymus. These therapeutic agents may take the form of polynucleotides comprising all or a portion of a nucleic acid of the invention comprising a regulatory
10 sequence of a C2GnT3 nucleic acid placed in appropriate vectors or delivered to target cells in more direct ways.

Having provided a novel C2GnT3, and nucleic acids encoding same, the invention accordingly further provides methods for preparing oligosaccharides. In specific embodi-
15 ments, the invention relates to a method for preparing an oligosaccharide comprising contacting a reaction mixture comprising a donor substrate, and an acceptor substrate in the presence of a C2GnT3 polypeptide of the invention.

20 In accordance with a further aspect of the invention, there are provided processes for utilizing polypeptides or nucleic acid molecules, for in vitro purposes related to scientific research, synthesis of DNA, and manufacture of vectors.

25 These and other aspects of the present invention will become evident upon reference to the following detailed description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the DNA sequence of the C2GnT3 gene (ac-
30 cession # AF132035) and the predicted amino acid sequence

of C2GnT3. The amino acid sequence is shown in single letter code. The hydrophobic segment representing the putative transmembrane domain is double underlined. Four consensus motifs for N-glycosylation are indicated by asterisks. The location of the primers used for preparation of the expression constructs are indicated by single underlining.

Figure 2 is an illustration of a sequence comparison between human C2GnT3 (accession # AF132035), human C2GnT2 (formerly designated C2/4GnT; accession # AF038650), human C2GnT1 (formerly designated C2GnT-L; accession # M97347), and human IGnT (accession # Z19550). Introduced gaps are shown as *hyphens*, and aligned identical residues are *box-shaded* (*black* for all sequences, *dark grey* for three sequences, and *light grey* for two sequences). The putative transmembrane domains are *boxed*. The positions of conserved cysteines are indicated by *asterisks*. One conserved N-glycosylation site is indicated by an *open circle*.

Figure 3 depicts Northern blot analyses of healthy human adult and fetal tissues. **Panel A:** loading pattern for the human mRNA master blot (CLONTECH). Dots in row H contain 100 ng (H1-H7) or 500 ng (H8) of control DNA or RNA. **Panel B:** autoradiogram of master blot expression analysis using a ^{32}P -labeled C2GnT3 probe corresponding to the soluble expression fragment of C2GnT3 (base pairs 115-1359). **Panel C:** A multiple human tissue northern blot (MTN II from Clontech) was probed as described for panel B.

Figure 4 shows a PCR analysis of C2GnT3 expression in human blood cell fractions. PCR amplifications with primers specific for human C2GnT3 (C2GnT3) or GAPDH (G3PDH) were performed on a normalized human blood cell cDNA panel (MTC from Clontech) for 31 cycles.

Figure 5 is a schematic representation of forward and reverse PCR primers that can be used to amplify the coding exon of the C2GnT3 gene. The sequences of the primers TSHC119 and TSHC123 are also shown.

5 DETAILED DESCRIPTION OF THE INVENTION

In the case of conflict,
the present description, including definitions, is in-
tended to control.

DEFINITIONS

1. "Nucleic acid" or "polynucleotide" as used herein refers to purine- and pyrimidine-containing polymers of any length, either polyribonucleotides or polydeoxyribonucleotides or mixed polyribo-polydeoxyribo nucleotides. This includes single- and double-stranded molecules, i.e., DNA-DNA, DNA-RNA and RNA-RNA hybrids, as well as "protein nucleic acids" (PNA) formed by conjugating bases to an amino acid backbone. This also includes nucleic acids containing modified bases (see below).

2. "Complementary DNA or cDNA" as used herein refers to a DNA molecule or sequence that has been enzymatically synthesized from the sequences present in a mRNA template, or a clone of such a DNA molecule. A "DNA Construct" is a DNA molecule or a clone of such a molecule, either single- or double-stranded, which has been modified to contain segments of DNA that are combined and juxtaposed in a manner that would not otherwise exist in nature. By way of non-limiting example, a cDNA or DNA which has no introns

is inserted adjacent to, or within, exogenous DNA sequences.

3. A plasmid or, more generally, a vector, is a DNA construct containing genetic information that may provide for its replication when inserted into a host cell. A plasmid generally contains at least one gene sequence to be expressed in the host cell, as well as sequences that facilitate such gene expression, including promoters and transcription initiation sites. It may be a linear or closed circular molecule.

4. Nucleic acids are "hybridizable" to each other when at least one strand of one nucleic acid can anneal to another nucleic acid under defined stringency conditions. Stringency of hybridization is determined, e.g., by a) the temperature at which hybridization and/or washing is performed, and b) the ionic strength and polarity (e.g., formamide) of the hybridization and washing solutions, as well as other parameters. Hybridization requires that the two nucleic acids contain substantially complementary sequences; depending on the stringency of hybridization, however, mismatches may be tolerated. Typically, hybridization of two sequences at high stringency (such as, for example, in an aqueous solution of 0.5X SSC, at 65°C) requires that the sequences exhibit some high degree of complementarity over their entire sequence. Conditions of intermediate stringency (such as, for example, an aqueous solution of 2X SSC at 65°C) and low stringency (such as, for example, an aqueous solution of 2X SSC at 55°C), require correspondingly less overall complementarity between the hybridizing sequences. (1X SSC is 0.15 M NaCl, 0.015 M Na citrate).

5. An "isolated" nucleic acid or polypeptide as used herein refers to a component that is removed from its

original environment (for example, its natural environment if it is naturally occurring). An isolated nucleic acid or polypeptide contains less than about 50%, preferably less than about 75%, and most preferably less than about 5 90%, of the cellular components with which it was originally associated.

6. A "probe" refers to a nucleic acid that forms a hybrid structure with a sequence in a target region due to complementarily of at least one sequence in the probe with a 10 sequence in the target region.

7. A nucleic acid that is "derived from" a designated sequence refers to a nucleic acid sequence that corresponds to a region of the designated sequence. This encompasses sequences that are homologous or complementary to the 15 sequence, as well as "sequence-conservative variants" and "function-conservative variants". Sequence-conservative variants are those in which a change of one or more nucleotides in a given codon position results in no alteration in the amino acid encoded at that position. Function-conservative variants of C2GnT3 are those in which a given 20 amino acid residue in the polypeptide has been changed without altering the overall conformation and enzymatic activity (including substrate specificity) of the native polypeptide; these changes include, but are not limited to, replacement of an amino acid with one having similar 25 physico-chemical properties (such as, for example, acidic, basic, hydrophobic, and the like).

8. A "donor substrate" is a molecule recognized by, e.g., a Core- β 1,6-N-acetylglucosaminyltransferase and that contributes an N-acetylglucosaminyl moiety for the transferase reaction. For C2GnT3, a donor substrate is UDP-N-acetylglucosamine. An "acceptor substrate" is a molecule, 30 preferably a saccharide or oligosaccharide, that is recog-

nized by, e.g., an *N*-acetylglucosaminyltransferase and that is the target for the modification catalyzed by the transferase, i.e., receives the *N*-acetylglucosaminyl moiety. For C2GnT3, acceptor substrates include without
5 limitation oligosaccharides, glycoproteins, *O*-linked core 1-glycopeptides, and glycosphingolipids comprising the sequences Gal β 1-3GalNAc, or GlcNAc β 1-3GalNAc.

9. In accordance with the present invention there may be employed conventional molecular biology, microbiology,
10 and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See for example, Sambrook, Fritsch, Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring
15 Harbor, N.Y); DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization B.D. Hames & S.J. Higgins eds. (1985); Transcription and Translation B.D. Hames & S.J. Higgins eds (1984); Animal
20 Cell Culture R.I. Freshney, ed. (1986); Immobilized Cells and enzymes IRL Press, (1986); and B. Perbal, A Practical Guide to Molecular Cloning (1984).

10. The terms "sequence similarity" or "sequence identity" refer to the relationship between two or more
25 amino acid or nucleic acid sequences, determined by comparing the sequences, which relationship is generally known as "homology". Identity in the art also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined
30 by the match between strings of such sequences. Both identity and similarity can be readily calculated (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press New York, 1988; Biocomputing:

Informatics and Genome Projects, Smith, D.W. ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G. eds. Humana Press, New Jersey, 1994; Sequence Analysis in
5 Molecular Biology, von Heinje, G., Academic Press, New York, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, S., eds. M. Stockton Press, New York, 1991). While there are a number of existing methods to measure identity and similarity between two amino acid
10 sequences or two nucleic acid sequences, both terms are well known to the skilled artisan (Sequence Analysis in Molecular Biology, von Hinge, G., Academic Press, New York, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds. M. Stockton Press, New York, 1991; and
15 Carillo, H., and Lipman, D. SIAM J. Applied Math., 48.1073, 1988). Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Preferred computer program
20 methods for determining identity and similarity between two sequences include but are not limited to the GCG program package (20), BLASTP, BLASTN, and FASTA (21). Identity or similarity may also be determined using the alignment algorithm of Dayhoff et al. (Methods in
25 Enzymology 91: 524-545 (1983)].

Preferably the nucleic acids of the present invention have substantial sequence identity using the preferred computer programs cited herein, for example greater than 40%, 45%, 50%, 60%, 70%, 75%, 80%, 85%, or 90% identity;
30 more preferably at least 95%, 96%, 97%, 98%, or 99% sequence identity to the sequence shown in SEQ ID NO: 1 and Figure 1.

11. The polypeptides of the invention also include homologs of a C2GnT3 polypeptide and/or truncations thereof as described herein. Such homologs include polypeptides whose amino acid sequences are comprised of the amino acid sequences of C2GnT3 polypeptide regions from other species that hybridize under selected hybridization conditions (see discussion of hybridization conditions in particular stringent hybridization conditions herein) with a probe used to obtain a C2GnT3 polypeptide. These homologs will generally have the same regions which are characteristic of a C2GnT3 polypeptide. It is anticipated that a polypeptide comprising an amino acid sequence which has at least 40% identity or at least 60% similarity, preferably at least 60-65% identity or at least 80-85% similarity, more preferably at least 70-80% identity or at least 90-95% similarity, most preferably at least 95% identity or at least 99% similarity with the amino acid sequence shown in SEQ ID NO: 2 and Figures 1 and 2, will be a homolog of a C2GnT3 polypeptide. A percent amino acid sequence similarity or identity is calculated using the methods described herein, preferably the computer programs described herein.

IDENTIFICATION AND CLONING OF C2GnT3

The present invention provides the isolated DNA molecules, including genomic DNA and cDNA, encoding the UDP-N-acetylglucosamine: N-acetylgalactosamine β 1,6 N-acetylglucosaminyltransferase 3 (C2GnT3).

C2GnT3 was identified by analysis of genomic survey sequences (GSS), and cloned based on a genomic clone obtained from a human foreskin fibroblast library. The cloning strategy may be briefly summarized as follows: 1) isolation and sequencing of GSS clone CIT-HSP-2288B17.TF

(GSS GenBank accession number AQ005888); 2) synthesis of oligonucleotides derived from GSS sequence information, designated TSHC96 and TSHC101; 3) identification, cloning and sequencing of genomic P1 clone GS22597 #844/B1; 4) 5 identification of a novel cDNA sequence corresponding to C2GnT3; 5) confirmatory sequencing of a cDNA clone obtained by reverse-transcription-polymerase chain reaction (RT-PCR) using human thymus poly A-mRNA; 6) construction of expression constructs; 7) expression of the cDNA encoding C2GnT3 in Sf9 (*Spodoptera frugiperda*) cells. More specifically, the isolation of a representative DNA molecule encoding a novel third member of the mammalian UDP-N-acetylglucosamine: β -N-acetylgalactosamine β 1,6-N-acetylglucosaminyltransferase family involved the following procedures described below. 15

Identification of DNA Homologous to C2/4GnT (C2GnT2)

Database searches were performed with the coding sequence of the human C2/4GnT (C2GnT2) sequence (13) using the BLASTn and the tBLASTn algorithm with the GSS database at 20 The National Center for Biotechnology Information, USA. The BLASTn algorithm was used to identify clones representing the query gene (identities of $\geq 95\%$), whereas tBLASTn was used to identify non-identical, but similar GSS sequences. GSSs with 50-90% nucleotide sequence identity were regarded as different from the query sequence. 25 Two GSS clones with several apparent short sequence motifs and cysteine residues arranged with similar spacing were selected for further sequence analysis.

Cloning of Human C2GnT3

30 GSS clone CIT-HSP-2288B17.TF (GSS GenBank accession number AQ005888), derived from a putative homologue to

C2/4GnT (C2GnT2), was obtained from Research Genetics Inc., USA. Sequencing of this clone revealed a partial open reading frame with significant sequence similarity to C2/4GnT (C2GnT2). The coding region of human C2GnT-L (C2GnT1), C2/4GnT (C2GnT2) and a bovine homologue was previously found to be organized in one exon ((22), (15)). Since the 3' sequence available from the C2GnT3 GSS was incomplete but likely to be located in a single exon, the missing 3' portion of the open reading frame was obtained by sequencing a genomic P1 clone. The P1 clone was obtained from a human foreskin genomic P1 library (DuPont Merck Pharmaceutical Co. Human Foreskin Fibroblast P1 Library) by screening with the primer pair TSHC96 (5'-GGTTTCACCGTCTCCAACATA-3', SEQ ID NO: 3) and TSHC101 (5'-TCGTAAGGCACCTGATACTT-3', SEQ ID NO: 6).

One genomic clone for C2GnT3, GS22597 #844/B1 was obtained from Genome Systems Inc. DNA from P1 phage was prepared as recommended by Genome Systems Inc. The entire coding sequence of the C2GnT3 gene was represented in the clone and sequenced in full using automated sequencing (ABI377, Perkin-Elmer). Confirmatory sequencing was performed on a cDNA clone obtained by PCR (30 cycles at 95 °C for 10 sec; 55 °C for 15 sec and 68 °C for 2 min 30 sec) on cDNA from human thymus poly A-mRNA with the sense primer TSHC99 (5'-CGAGGATCCAGAATGAAGATATTCAAATGTTA-3', SEQ ID NO: 4) and the anti-sense primer TSHC121 (5'-AGCGAATTCTTACTATCATGATGTGGTAGTG-3', SEQ ID NO: 9). The composite sequence contained an open reading frame of 1359 base pairs encoding a putative protein of 453 amino acids with type II domain structure predicted by the TMpred-algorithm at the Swiss Institute for Experimental Cancer Research (ISREC) (http://www.ch.embnet.org/software/TMPRED_form.html).

Expression of C2GnT3

An expression construct designed to encode amino acid residues 39-453 of C2GnT3 was prepared by PCR using P1 DNA, and the primer pair

5 TSHC100 (5'-CGAGGATCCGCAAAAAGACATTTACTTGGTT -3', SEQ ID NO: 5) and TSHC121 (5'-AGCGAATTCTTACTATCATGATGTGGTAGTG-3', SEQ ID NO: 9) with *Bam*HI and *Eco*RI restriction sites, respectively (Fig. 2). The PCR product was cloned between the *Bam*HI and *Eco*RI sites of pAcGP67A (PharMingen), and

10 the insert was fully sequenced. pAcGP67-C2GnT3-sol was co-transfected with Baculo-GoldTM DNA (PharMingen) as described previously (23). Recombinant Baculovirus was obtained after two successive amplifications in Sf9 cells grown in serum-containing medium, and titers of virus

15 were estimated by titration in 24-well plates with monitoring of enzyme activities. Transfection of Sf9-cells with pAcGP67-C2GnT3-sol resulted in marked increase in GlcNAc-transferase activity compared to uninfected cells or cells infected with a control construct. C2GnT3 showed

20 significant activity with disaccharide derivatives of O-linked core 1 (Gal β 1-3GalNAc α 1-R). In contrast, no activity was found with core 3 structures (GlcNAc β 1-3GalNAc α 1-R), lacto-*N*-neotetraose as well as GlcNAc β 1-3Gal-Me as acceptor substrates indicating that C2GnT3 has no

25 Core4GnT and IGnT-activity. Additionally, no activity could be detected with α -D-GalNAc-1- *para*-nitrophenyl indicating that C2GnT3 does not form core 6 (GlcNAc β 1-6GalNAc α 1-R) (Table I). No substrate inhibition of enzyme activity was found at high acceptor concentrations up to

30 20 mM core 1-*para*-nitrophenyl. C2GnT3 shows strict donor substrate specificity for UDP-GlcNAc, no activity could be detected with UDP-Gal or UDP-GalNAc (data not shown).

Table I: Substrate specificities of C2GnT3 and C2GnT1

Substrate	C2GnT3 ^a		C2GnT1	
	2 mM	10 mM	2 mM	10 mM
	<i>nmol / h / mg</i>		<i>nmol / h / mg</i>	
β -D-Gal-(1-3)- α -D-GalNAc	6.6	14.3	9.6	19.0
β -D-Gal-(1-3)- α -D-GalNAc-1- <i>p</i> -Nph	18.1	26.1	16.2	23.6
β -D-GlcNAc-(1-3)- α -D-GalNAc-1- <i>p</i> -Nph	<0.1	<0.1	<0.1	<0.1
α -D-GalNAc-1- <i>p</i> -Nph	<0.1	<0.1	<0.1	<0.1
D-GalNAc	<0.1	<0.1	<0.1	<0.1
lacto- <i>N-neo</i> -tetraose	<0.1	<0.1	<0.1	<0.1
β -D-GlcNAc-(1-3)- β -D-Gal-1-Me	<0.1	<0.1	<0.1	<0.1

^aEnzyme sources were partially purified media of infected High Five™ cells (see "Experimental Procedures"). Background values obtained with uninfected cells or cells infected with an irrelevant construct were subtracted. ^bMe, methyl; Nph, nitrophenyl.

- 5 Controls included the pAcGP67-GalNAc-T3-sol (24). The kinetic properties were determined with partially purified enzymes expressed in High Five™ cells. Partial purification was performed by consecutive chromatography on Am-
 10 berlite IRA-95, DEAE-Sephacryl and SP-Sepharose essentially as described (25; 25).

Northern Blot analysis of Human Organs

A human RNA master blot containing mRNA from fifty healthy human adult and fetal organs (CLONTECH) and a human multiple tissue northern blot (MTNII from CLONTECH) were probed
 15 with a ³²P-labeled probe corresponding to the soluble fragment of C2GnT3 (base pairs 115-1359). The autoradiographic analyses showed expression of C2GnT3 predominantly in lymphoid organs and in organs of the gastrointestinal tract with high transcription levels observed in thymus,
 20 and lower levels in PBLs, lymph node, stomach, pancreas and small intestine (Fig. 3A and 3B). The size of the single transcript was approximately 5.5 kilobases, which correlates to the transcript size of 5.4 kilobases of the

biggest of three transcripts of human C2GnT1 (Fig. 3C). Multiple transcripts of C2GnT1 have been suggested to be caused by differential usage of polyadenylation signals, which affects the length of the 3' UTR (13).

5 The C2GnT3 enzyme of the present invention was shown to exhibit O-glycosylation capacity implying that the C2GnT3 gene is vital for correct/full O-glycosylation *in vivo* as well. A structural defect in the C2GnT3 gene leading to a deficient enzyme or completely defective enzyme would
10 therefore expose a cell or an organism to protein/peptide sequences which were not covered by O-glycosylation as seen in cells or organisms with intact C2GnT3 gene. Described in Example 5 below is a method for scanning the coding exon for potential structural defects. Similar
15 methods could be used for the characterization of defects in the non-coding region of the C2GnT3 gene including the promoter region.

DNA, Vectors, and Host Cells

In practicing the present invention, many conventional
20 techniques in molecular biology, microbiology, recombinant DNA, and immunology, are used. Such techniques are well known and are explained fully in, for example, Sambrook et al., 1989, *Molecular Cloning A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring
25 Harbor, New York; *DNA Cloning: A Practical Approach*, Volumes I and II, 1985 (D.N. Glover ed.); *Oligonucleotide Synthesis*, 1984, (M.L. Gait ed.); *Nucleic Acid Hybridization*, 1985, (Hames and Higgins); *Transcription and Translation*, 1984 (Hames and Higgins eds.); *Animal Cell Cul-*
30 *ture*, 1986 (R.I. Freshney ed.); *Immobilized Cells and Enzymes*, 1986 (IRL Press); Perbal, 1984, *A Practical Guide to Molecular Cloning*; the series, *Methods in Enzymology*

(Academic Press, Inc.); *Gene Transfer Vectors for Mammalian Cells*, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); *Methods in Enzymology* Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively); *Immunochemical Methods in Cell and Molecular Biology*, 1987 (Mayer and Waler, eds; Academic Press, London); Scopes, 1987, *Protein Purification: Principles and Practice*, Second Edition (Springer-Verlag, N.Y.) and *Handbook of Experimental Immunology*, 1986, Volumes I-IV (Weir and Blackwell eds.).

The invention encompasses isolated nucleic acid fragments comprising all or part of the nucleic acid sequence disclosed herein as set forth in Figure 1. The fragments are at least about 8 nucleotides in length, preferably at least about 12 nucleotides in length, and most preferably at least about 15-20 nucleotides in length. The invention further encompasses isolated nucleic acids comprising sequences that are hybridizable under stringency conditions of 2X SSC, 55 °C, to the sequence set forth in Figure 1; preferably, the nucleic acids are hybridizable at 2X SSC, 65 °C; and most preferably, are hybridizable at 0.5X SSC, 65 °C.

The nucleic acids may be isolated directly from cells. Alternatively, the polymerase chain reaction (PCR) method can be used to produce the nucleic acids of the invention, using either chemically synthesized strands or genomic material as templates. Primers used for PCR can be synthesized using the sequence information provided herein and can further be designed to introduce appropriate new restriction sites, if desirable, to facilitate incorporation into a given vector for recombinant expression.

The nucleic acids of the present invention may be flanked by natural human regulatory sequences, or may be associ-

ated with heterologous sequences, including promoters, enhancers, response elements, signal sequences, polyadenylation sequences, introns, 5'- and 3'- noncoding regions, and the like. The nucleic acids may also be modified by
5 many means known in the art. Non-limiting examples of such modifications include methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoroamidates, carbamates,
10 etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.). Nucleic acids may contain one or more additional covalently linked moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators
15 (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive metals, iron, oxidative metals, etc.), and alkylators. The nucleic acid may be derivatized by formation of a methyl or ethyl phosphotriester or an alkyl phosphoramidate linkage. Furthermore, the nucleic acid sequences
20 of the present invention may also be modified with a label capable of providing a detectable signal, either directly or indirectly. Exemplary labels include radioisotopes, fluorescent molecules, biotin, and the like.

25 According to the present invention, useful probes comprise a probe sequence at least eight nucleotides in length that consists of all or part of the sequence from among the sequences as set forth in Figure 1 or sequence-conservative or function-conservative variants thereof, or a complement
30 thereof, and that has been labelled as described above.

The invention also provides nucleic acid vectors comprising the disclosed sequence or derivatives or fragments thereof. A large number of vectors, including plasmid and

fungus vectors, have been described for replication and/or expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple cloning or protein expression.

5 Recombinant cloning vectors will often include one or more replication systems for cloning or expression, one or more markers for selection in the host, e.g. antibiotic resistance, and one or more expression cassettes. The inserted coding sequences may be synthesized by standard methods,
10 isolated from natural sources, or prepared as hybrids, etc. Ligation of the coding sequences to transcriptional regulatory elements and/or to other amino acid coding sequences may be achieved by known methods. Suitable host cells may be transformed/transfected/infected as appropriate by any suitable method including electroporation,
15 CaCl_2 mediated DNA uptake, fungal infection, microinjection, microprojectile, or other established methods.

Appropriate host cells included bacteria, archaeobacteria, fungi, especially yeast, and plant and animal cells, especially mammalian cells. Of particular interest are *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Hansenula polymorpha*, *Neurospora spec.*, SF9
20 cells, C129 cells, 293 cells, and CHO cells, COS cells, HeLa cells, and immortalized mammalian myeloid and lymphoid cell lines. Preferred replication systems include M13, ColE1, 2 μ , ARS, SV40, baculovirus, lambda, adenovirus, and the like. A large number of transcription initiation and termination regulatory regions have been isolated and shown to be effective in the transcription and translation of heterologous proteins in the various hosts. Examples of these regions, methods of isolation, manner of
25 manipulation, etc. are known in the art. Under appropriate expression conditions, host cells can be used as a source
30

of recombinantly produced C2GnT3 derived peptides and polypeptides.

Advantageously, vectors may also include a transcription regulatory element (i.e., a promoter) operably linked to the C2GnT3 coding portion. The promoter may optionally contain operator portions and/or ribosome binding sites. Non-limiting examples of bacterial promoters compatible with *E. coli* include: β -lactamase (penicillinase) promoter; lactose promoter; tryptophan (trp) promoter; arabinose BAD operon promoter; lambda-derived P₁ promoter and N gene ribosome binding site; and the hybrid tac promoter derived from sequences of the trp and lac UV5 promoters. Non-limiting examples of yeast promoters include 3-phosphoglycerate kinase promoter, glyceraldehyde-3 phosphate dehydrogenase (GAPDH) promoter, galactokinase (GAL1) promoter, galactose epimerase (GAL10) promoter, metallothioneine (CUP) promoter and alcohol dehydrogenase (ADH) promoter. Suitable promoters for mammalian cells include without limitation viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), and bovine papilloma virus (BPV). Mammalian cells may also require terminator sequences and poly A addition sequences and enhancer sequences which increase expression may also be included; sequences which cause amplification of the gene may also be desirable. Furthermore, sequences that facilitate secretion of the recombinant product from cells, including, but not limited to, bacteria, yeast, and animal cells, such as secretory signal sequences and/or prohormone pro region sequences, may also be included. These sequences are known in the art.

Nucleic acids encoding wild type or variant polypeptides may also be introduced into cells by recombination events. For example, such a sequence can be introduced into a

cell, and thereby effect homologous recombination at the site of an endogenous gene or a sequence with substantial identity to the gene. Other recombination-based methods such as nonhomologous recombinations or deletion of endogenous genes by homologous recombination may also be
5 used.

The nucleic acids of the present invention find use, for example, as probes for the detection of C2GnT3 in other species or related organisms and as templates for the re-
10 combinant production of peptides or polypeptides. These and other embodiments of the present invention are described in more detail below.

Polypeptides and Antibodies

The present invention encompasses isolated peptides and
15 polypeptides encoded by the disclosed cDNA sequence. Peptides are preferably at least five residues in length.

Nucleic acids comprising protein-coding sequences can be used to direct the recombinant expression of polypeptides in intact cells or in cell-free translation systems. The
20 known genetic code, tailored if desired for more efficient expression in a given host organism, can be used to synthesize oligonucleotides encoding the desired amino acid sequences. The phosphoramidite solid support method of (26), the method of (27), or other well known methods can
25 be used for such synthesis. The resulting oligonucleotides can be inserted into an appropriate vector and expressed in a compatible host organism.

The polypeptides of the present invention, including function-conservative variants of the disclosed sequence, may
30 be isolated from native or from heterologous organisms or cells (including, but not limited to, bacteria, fungi, in-

sect, plant, and mammalian cells) into which a protein-coding sequence has been introduced and expressed. Furthermore, the polypeptides may be part of recombinant fusion proteins.

- 5 Methods for polypeptide purification are well known in the art, including, without limitation, preparative discontinuous gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. For
10 some purposes, it is preferable to produce the polypeptide in a recombinant system in which the protein contains an additional sequence tag that facilitates purification, such as, but not limited to, a polyhistidine sequence. The polypeptide can then be purified from a crude lysate of
15 the host cell by chromatography on an appropriate solid-phase matrix. Alternatively, antibodies produced against a protein or against peptides derived therefrom can be used as purification reagents. Other purification methods are possible.
- 20 The present invention also encompasses derivatives and homologues of polypeptides. For some purposes, nucleic acid sequences encoding the peptides may be altered by substitutions, additions, or deletions that provide for functionally equivalent molecules, i.e., function-conservative variants. For example, one or more amino acid residues
25 within the sequence can be substituted by another amino acid of similar properties, such as, for example, positively charged amino acids (arginine, lysine, and histidine); negatively charged amino acids (aspartate and glutamate); polar neutral amino acids; and non-polar amino
30 acids.

The isolated polypeptides may be modified by, for example, phosphorylation, sulfation, acylation, or other protein

modifications. They may also be modified with a label capable of providing a detectable signal, either directly or indirectly, including, but not limited to, radioisotopes and fluorescent compounds.

- 5 The present invention encompasses antibodies that specifically recognize immunogenic components derived from C2GnT3. Such antibodies can be used as reagents for detection and purification of C2GnT3.

10 C2GnT3 specific antibodies according to the present invention include polyclonal and monoclonal antibodies. The antibodies may be elicited in an animal host by immunization with C2GnT3 components or may be formed by *in vitro* immunization of immune cells. The immunogenic components used to elicit the antibodies may be isolated from human
15 cells or produced in recombinant systems. The antibodies may also be produced in recombinant systems programmed with appropriate antibody-encoding DNA. Alternatively, the antibodies may be constructed by biochemical reconstitution of purified heavy and light chains. The antibodies
20 include hybrid antibodies (i.e., containing two sets of heavy chain/light chain combinations, each of which recognizes a different antigen), chimeric antibodies (i.e., in which either the heavy chains, light chains, or both, are fusion proteins), and univalent antibodies (i.e., comprised of a heavy chain/light chain complex bound to the
25 constant region of a second heavy chain). Also included are Fab fragments, including Fab' and F(ab)₂ fragments of antibodies. Methods for the production of all of the above types of antibodies and derivatives are well known in the
30 art. For example, techniques for producing and processing polyclonal antisera are disclosed in Mayer and Walker, 1987, *Immunochemical Methods in Cell and Molecular Biology*, (Academic Press, London).

The antibodies of this invention can be purified by standard methods, including but not limited to preparative disc-gel electrophoresis, isoelectric focusing, HPLC, reversed-phase HPLC, gel filtration, ion exchange and partition chromatography, and countercurrent distribution. Purification methods for antibodies are disclosed, e.g., in *The Art of Antibody Purification*, 1989, Amicon Division, W.R. Grace & Co. General protein purification methods are described in *Protein Purification: Principles and Practice*, R.K. Scopes, Ed., 1987, Springer-Verlag, New York, NY.

Anti C2GnT3 antibodies, whether unlabeled or labeled by standard methods, can be used as the basis for immunoassays. The particular label used will depend upon the type of immunoassay used. Examples of labels that can be used include, but are not limited to, radiolabels such as ^{32}P , ^{125}I , ^3H and ^{14}C ; fluorescent labels such as fluorescein and its derivatives, rhodamine and its derivatives, dansyl and umbelliferone; chemiluminescers such as luciferia and 2,3-dihydrophthalazinediones; and enzymes such as horseradish peroxidase, alkaline phosphatase, lysozyme and glucose-6-phosphate dehydrogenase.

The antibodies can be tagged with such labels by known methods. For example, coupling agents such as aldehydes, carbodiimides, dimaleimide, imidates, succinimides, bisdiazotized benzadine and the like may be used to tag the antibodies with fluorescent, chemiluminescent or enzyme labels. The general methods involved are well known in the art and are described in, e.g., Chan (Ed.), 1987, *Immunoassay: A Practical Guide*, Academic Press, Inc., Orlando, FL.

***APPLICATIONS OF THE NUCLEIC ACID MOLECULES, POLYPEPTIDES,
AND ANTIBODIES OF THE INVENTION***

The nucleic acid molecules, C2GnT3 polypeptide, and anti-
bodies of the invention may be used in the prognostic and
5 diagnostic evaluation of conditions associated with al-
tered expression or activity of a polypeptide of the in-
vention or conditions requiring modulation of a nucleic
acid or polypeptide of the invention including thymus-
related disorders and proliferative disorders (e.g. can-
10 cer), and the identification of subjects with a predispo-
sition to such conditions (See below). Methods for de-
tecting nucleic acid molecules and polypeptides of the
invention can be used to monitor such conditions by de-
tecting and localizing the polypeptides and nucleic ac-
15 ids. It would also be apparent to one skilled in the art
that the methods described herein may be used to study
the developmental expression of the polypeptides of the
invention and, accordingly, will provide further insight
into the role of the polypeptides. The applications of
20 the present invention also include methods for the iden-
tification of substances or compounds that modulate the
biological activity of a polypeptide of the invention
(See below). The substances, compounds, antibodies etc.,
may be used for the treatment of conditions requiring
25 modulation of polypeptides of the invention (See below).

Diagnostic Methods

A variety of methods can be employed for the diagnostic
and prognostic evaluation of conditions requiring modula-
tion of a nucleic acid or polypeptide of the invention
30 (e.g. thymus-related disorders, and cancer), and the
identification of subjects with a predisposition to such
conditions. Such methods may, for example, utilize nu-

cleic acids of the invention, and fragments thereof, and antibodies directed against polypeptides of the invention, including peptide fragments. In particular, the nucleic acids and antibodies may be used, for example, for:

5 (1) the detection of the presence of C2GnT3 mutations, or the detection of either over- or under-expression of C2GnT3 mRNA relative to a non-disorder state or the qualitative or quantitative detection of alternatively spliced forms of C2GnT3 transcripts which may correlate

10 with certain conditions or susceptibility toward such conditions; or (2) the detection of either an over- or an under-abundance of a polypeptide of the invention relative to a non-disorder state or the presence of a modified (e.g., less than full length) polypeptide of the invention

15 which correlates with a disorder state, or a progression toward a disorder state.

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least one specific nucleic acid or antibody described herein, which

20 may be conveniently used, e.g., in clinical settings, to screen and diagnose patients and to screen and identify those individuals exhibiting a predisposition to developing a disorder.

Nucleic acid-based detection techniques and peptide detection techniques are described below. The samples that

25 may be analyzed using the methods of the invention include those that are known or suspected to express C2GnT3 nucleic acids or contain a polypeptide of the invention. The methods may be performed on biological samples including but not limited to cells, lysates of cells which

30 have been incubated in cell culture, chromosomes isolated from a cell (e.g. a spread of metaphase chromosomes), genomic DNA (in solutions or bound to a solid support such

as for Southern analysis), RNA (in solution or bound to a solid support such as for northern analysis), cDNA (in solution or bound to a solid support), an extract from cells or a tissue, and biological fluids such as serum, urine, blood, and CSF. The samples may be derived from a patient or a culture.

Methods for Detection of Nucleic Acid Molecules of the Invention

The nucleic acid molecules of the invention allow those skilled in the art to construct nucleotide probes for use in the detection of nucleic acid sequences of the invention in biological materials. Suitable probes include nucleic acid molecules based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of the C2GnT3 polypeptide (see SEQ ID NO: 1), preferably they comprise 15 to 50 nucleotides, more preferably 15 to 40 nucleotides, most preferably 15-30 nucleotides. A nucleotide probe may be labelled with a detectable substance such as a radioactive label that provides for an adequate signal and has sufficient half-life such as ^{32}P , ^3H , ^{14}C or the like. Other detectable substances that may be used include antigens that are recognized by a specific labelled antibody, fluorescent compounds, enzymes, antibodies specific for a labelled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labelled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect C2GnT3 genes, preferably in

human cells. The nucleotide probes may also be used for example in the diagnosis or prognosis of conditions such as thymus-related disorders and cancer, and in monitoring the progression of these conditions, or monitoring a
5 therapeutic treatment.

The probe may be used in hybridisation techniques to detect a C2GnT3 gene. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from
10 a patient or other cellular source with a probe of the present invention under conditions favourable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of
15 nucleic acids that have hybridized to the probe if any are detected.

The detection of nucleic acid molecules of the invention may involve the amplification of specific gene sequences using an amplification method (e.g. PCR), followed by the
20 analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed by one of skill in the art. For example, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software
25 ware (National Biosciences, Plymouth, Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 60 °C to 72 °C.

30 Genomic DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving C2GnT3 nucleic acid structure, including point mutations, insertions, deletions, and chromosomal rear-

rangements. For example, direct sequencing, single stranded conformational polymorphism analyses, heteroduplex analysis, denaturing gradient gel electrophoresis, chemical mismatch cleavage, and oligonucleotide hybridization may be utilized.

Genotyping techniques known to one skilled in the art can be used to type polymorphisms that are in close proximity to the mutations in a C2GnT3 gene. The polymorphisms may be used to identify individuals in families that are likely to carry mutations. If a polymorphism exhibits linkage disequilibrium with mutations in the G2GnT3 gene, it can also be used to screen for individuals in the general population likely to carry mutations. Polymorphisms which may be used include restriction fragment length polymorphisms (RFLPs), single-nucleotide polymorphisms (SNP), and simple sequence repeat polymorphisms (SSLPs).

A probe or primer of the invention may be used to directly identify RFLPs. A probe or primer of the invention can additionally be used to isolate genomic clones such as YACs, BACs, PACs, cosmids, phage or plasmids. The DNA in the clones can be screened for SSLPs using hybridization or sequencing procedures.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of C2GnT3 expression. For example RNA may be isolated from a cell type or tissue known to express C2GnT3 and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein. The techniques may be used to detect differences in transcript size that may be due to normal or abnormal alternative splicing. The techniques may be used to detect quantitative differences between levels of full length and/or alternatively splice transcripts detected in nor-

mal individuals relative to those individuals exhibiting symptoms of a disease.

The primers and probes may be used in the above described methods *in situ* i.e directly on tissue sections (fixed
5 and/or frozen) of patient tissue obtained from biopsies or resections.

Oligonucleotides or longer fragments derived from any of the nucleic acid molecules of the invention may be used as targets in a microarray. The microarray can be used to
10 simultaneously monitor the expression levels of large numbers of genes and to identify genetic variants, mutations, and polymorphisms. The information from the microarray may be used to determine gene function, to understand the genetic basis of a disorder, to identify
15 predisposition to a disorder, to treat a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of micro arrays are well known to a person skilled in the art. (see, for
20 example, Brennan, T. M., et al. (1995), U.S. Patent No. 5,474,796; Schena et al. (1996), Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application W095/251116; Shalon, D., et al. (1995), PCT application W095/35505; Heller, R. A., et al. (1997), Proc.
25 Natl. Acad. Sci. 94:2150-2155; and Heller, M. J., et al. (1997), U.S. Patent No. 5,605,662.)

Methods for Detecting Polypeptides

Antibodies specifically reactive with a C2GnT3 Polypeptide, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect C2GnT3 polypeptides in various biological materials. They may be used
30

as diagnostic or prognostic reagents and they may be used to detect abnormalities in the level of C2GnT3 polypeptides, expression, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of the polypeptides. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on a condition such as a thymus-related disorder or cancer. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies.

The antibodies of the invention may also be used *in vitro* to determine the level of C2GnT3 polypeptide expression in cells genetically engineered to produce a C2GnT3 polypeptide. The antibodies may be used to detect and quantify polypeptides of the invention in a sample in order to determine their role in particular cellular events or pathological states, and to diagnose and treat such pathological states.

In particular, the antibodies of the invention may be used in immuno-histochemical analyses, for example, at the cellular and sub-subcellular level, to detect a polypeptide of the invention, to localize it to particular cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

The antibodies may be used in any known immunoassays that rely on the binding interaction between an antigenic determinant of a polypeptide of the invention, and the antibodies. Examples of such assays are radio immunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation, latex agglutination, hemagglutination, and histochemical tests,

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect a polypeptide of the invention. Generally, an antibody of the invention may be labelled with a detect-
5 able substance and a polypeptide may be localised in tissues and cells based upon the presence of the detectable substance. Various methods of labelling polypeptides are known in the art and may be used. Examples of detectable substances include, but are not limited to, the follow-
10 ing: radioisotopes (e.g., ^3H , ^{14}C , ^{35}S , ^{125}I , ^{131}I), fluorescent labels (e.g., FITC, Rhodamine, lanthanide phosphors), luminescent labels such as luminol, enzymatic labels (e.g., horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase),
15 biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or calorimetric methods), predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper
20 pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as
25 ferritin or colloidal gold, which are readily visualised by electron microscopy.

The antibody or sample may be immobilized on a carrier or solid support which is capable of immobilizing cells, antibodies, etc. For example, the carrier or support may be
30 nitrocellulose, or glass, polyacrylamides, gabbros, and magnetite. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test

strip). Indirect methods may also be employed in which the primary antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against a polypeptide of the invention. By way of example, if the antibody having specificity against a polypeptide of the invention is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labelled with a detectable substance as described herein.

Where a radioactive label is used as a detectable substance, a polypeptide of the invention may be localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

A polypeptide of the invention may also be detected by assaying for C2GnT3 activity as described herein. For example, a sample may be reacted with an acceptor substrate and a donor substrate under conditions where a C2GnT3 polypeptide is capable of transferring the donor substrate to the acceptor substrate to produce a donor substrate-acceptor substrate complex.

Methods for Identifying or Evaluating Substances / Compounds

The methods described herein are designed to identify substances and compounds that modulate the expression or biological activity of a C2GnT3 polypeptide including substances that interfere with or enhance the expression or activity of a C2GnT3 polypeptide.

Substances and compounds identified using the methods of the invention include but are not limited to peptides

such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)₂, and Fab expression library fragments, and epitope-binding fragments thereof)], polypeptides, nucleic acids, carbohydrates, and small organic or inorganic molecules. A substance or compound may be an endogenous physiological compound or it may be a natural or synthetic compound.

Substances which modulate a C2GnT3 polypeptide can be identified based on their ability to associate with a C2GnT3 polypeptide. Therefore, the invention also provides methods for identifying substances that associate with a C2GnT3 polypeptide. Substances identified using the methods of the invention may be isolated, cloned and sequenced using conventional techniques. A substance that associates with a polypeptide of the invention may be an agonist or antagonist of the biological or immunological activity of a polypeptide of the invention.

The term "agonist" refers to a molecule that increases the amount of, or prolongs the duration of, the activity of the polypeptide. The term "antagonist" refers to a molecule which decreases the biological or immunological activity of the polypeptide. Agonists and antagonists may include proteins, nucleic acids, carbohydrates, or any other molecules that associate with a polypeptide of the invention.

Substances which can associate with a C2GnT3 polypeptide may be identified by reacting a C2GnT3 polypeptide with a

test substance which potentially associates with a C2GnT3 polypeptide, under conditions which permit the association, and removing and/or detecting the associated C2GnT3 polypeptide and substance. The Substance-polypeptide complexes, free substance, or non-complexed polypeptides may be assayed. Conditions which permit the formation of substance-polypeptide complexes may be selected having regard to factors such as the nature and amounts of the substance and the polypeptide.

10 The substance-polypeptide complex, free substance or non-complexes polypeptides may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof. To facilitate the assay of the components, antibody against a polypeptide of the invention or the substance, or labelled polypeptide, or a labelled substance may be utilized. The antibodies, polypeptides, or substances may be labelled with a detectable substance as described above.

A C2GnT3 polypeptide, or the substance used in the method of the invention may be insolubilized. For example, a polypeptide, or substance may be bound to a suitable carrier such as agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc. The insolubilized polypeptide or substance may be prepared by reacting the material with a suitable

insoluble carrier using known chemical or physical methods, for example, cyanogen bromide coupling.

The invention also contemplates a method for evaluating a compound for its ability to modulate the biological activity of a polypeptide of the invention, by assaying for an agonist or antagonist (i.e. enhancer or inhibitor) of the association of the polypeptide with a substance which interacts with the polypeptide (e.g. donor or acceptor substrates or parts thereof). The basic method for evaluating if a compound is an agonist or antagonist of the association of a polypeptide of the invention and a substance that associates with the polypeptide is to prepare a reaction mixture containing the polypeptide and the substance under conditions which permit the formation of substance-polypeptide complexes, in the presence of a test compound. The test compound may be initially added to the mixture, or may be added subsequent to the addition of the polypeptide and substance. Control reaction mixtures without the test compound or with a placebo are also prepared. The formation of complexes is detected and the formation of complexes in the control reaction but not in the reaction mixture indicates that the test compound interferes with the interaction of the polypeptide and substance. The reactions may be carried out in the liquid phase or the polypeptide, substance, or test compound may be immobilized as described herein.

It will be understood that the agonists and antagonists i.e. inhibitors and enhancers, that can be assayed using the methods of the invention may act on one or more of the interaction sites on the polypeptide or substance including agonist binding sites, competitive antagonist binding sites, non-competitive antagonist binding sites or allosteric sites.

The invention also makes it possible to screen for antagonists that inhibit the effects of an agonist of the interaction of a polypeptide of the invention with a substance which is capable of associating with the polypeptide. Thus, the invention may be used to assay for a compound that competes for the same interacting site of a polypeptide of the invention.

Substances that modulate a C2GnT3 polypeptide of the invention can be identified based on their ability to interfere with or enhance the activity of a C2GnT3 polypeptide. Therefore, the invention provides a method for evaluating a compound for its ability to modulate the activity of a C2GnT3 polypeptide comprising (a) reacting an acceptor substrate and a donor substrate for a C2GnT3 polypeptide in the presence of a test substance; (b) measuring the amount of donor substrate transferred to acceptor substrate, and (c) carrying out steps (a) and (b) in the absence of the test substance to determine if the substance interferes with or enhances transfer of the sugar donor to the acceptor by the C2GnT3 polypeptide.

Suitable acceptor substrate for use in the methods of the invention are a saccharide, oligosaccharides, polysaccharides, polypeptides, glycopolypeptides, or glycolipids which are either synthetic with linkers at the reducing end or naturally occurring structures, for example, asialo-agalacto-fetuin glycopeptide. Acceptors will generally comprise β -D-galactosyl-1,3-N-acetyl-D-galactosaminyl-.

The donor substrate may be a nucleotide sugar, dolichol-phosphate-sugar or dolichol-pyrophosphate-oligosaccharide, for example, uridine diphospho-N-acetylglucosamine (UDP-GlcNAc), or derivatives or analogs thereof. The

C2GnT3 polypeptide may be obtained from natural sources or produced using recombinant methods as described herein.

The acceptor or donor substrates may be labeled with a detectable substance as described herein, and the interaction of the polypeptide of the invention with the acceptor and donor will give rise to a detectable change. The detectable change may be colorimetric, photometric, radiometric, potentiometric, etc. The activity of C2GnT3 polypeptide of the invention may also be determined using methods based on HPLC (Koenderman et al., FEBS Lett. 222: 42, 1987) or methods employing synthetic oligosaccharide acceptors attached to hydrophobic aglycones (Palcic et al Glycoconjugate 5:49, 1988; and Pierce et al, Biochem. Biophys. Res. Comm. 146: 679, 1987).

The C2GnT3 polypeptide is reacted with the acceptor and donor substrates at a pH and temperature effective for the polypeptide to transfer the donor to the acceptor, and where one of the components is labeled, to produce a detectable change. It is preferred to use a buffer with the acceptor and donor to maintain the pH within the pH range effective for the polypeptides. The buffer, acceptor and donor may be used as an assay composition. Other compounds such as EDTA and detergents may be added to the assay composition.

The reagents suitable for applying the methods of the invention to evaluate compounds that modulate a C2GnT3 polypeptide may be packaged into convenient kits providing the necessary materials packaged into suitable containers. The kits may also include suitable supports useful in performing the methods of the invention.

Substances that modulate a C2GnT3 polypeptide can also be identified by treating immortalized cells which express

the polypeptide with a test substance, and comparing the morphology of the cells with the morphology of the cells in the absence of the substance and/or with immortalized cells which do not express the polypeptide. Examples of
5 immortalized cells that can be used include lung epithelial cell lines such as Mv1Lu or HEK293 (human embryonal kidney) transfected with a vector containing a nucleic acid of the invention. In the absence of an inhibitor the cells show signs of morphologic transformation (e.g. fi-
10 broblastic morphology, spindle shape and pile up; the cells are less adhesive to substratum; there is less cell to cell contact in monolayer culture; there is reduced growth-factor requirements for survival and proliferation; the cells grow in soft-agar or other semi-solid me-
15 dium; there is a lack of contact inhibition and increased apoptosis in low-serum high density cultures; there is enhanced cell motility, and there is invasion into extracellular matrix and secretion of proteases). Substances that inhibit one or more phenotypes may be con-
20 sidered an inhibitor.

A substance that inhibits a C2GnT3 polypeptide may be identified by treating a cell which expresses the polypeptide with a test substance, and assaying for complex
25 core 2-based O-linked structures (e.g. repeating Gal[β]1-4GlcNAc[β]) associated with the cell. The complex core 2-based O-linked structures can be assayed using a substance that binds to the structures (e.g. antibodies). Cells that have not been treated with the substance or which do not express the polypeptide may be employed as
30 controls.

Substances which inhibit transcription or translation of a C2GnT3 gene may be identified by transfecting a cell with an expression vector comprising a recombinant mole-

cule of the invention, including a reporter gene, in the presence of a test substance and comparing the level of expression of the C2GnT3 polypeptide, or the expression of the polypeptide encoded by the reporter gene with a control cell transfected with the nucleic acid molecule in the absence of the substance. The method can be used to identify transcription and translation inhibitors of a C2GnT3 gene.

Compositions and Treatments

The substances or compounds identified by the methods described herein, polypeptides, nucleic acid molecules, and antibodies of the invention may be used for modulating the biological activity of a C2GnT3 polypeptide, and they may be used in the treatment of conditions mediated by a C2GnT3 polypeptide. In particular, they may be used to T-cell development and lymphocyte homing and they may be used in the prevention and treatment of thymus-related disorders.

Therefore, the present invention may be useful for diagnosis or treatment of various thymus-related disorders in mammals, preferably humans. Such disorders include the following: tumors and cancers, hypoactivity, hyperactivity, atrophy, enlargement of the thymus, and the like. Other disorders include dysregulation of T-lymphocyte selection or activity and would include but not be limited to disorders involving autoimmunity, arthritis, leukemias, lymphomas, immunosuppression, sepsis, wound healing, acute and chronic inflammation, cell mediated immunity, humoral immunity, TH1/TH2 imbalance, and the like.

The substances or compounds identified by the methods described herein, antibodies, and polypeptides, and nucleic

acid molecules of the invention may be useful in the prevention and treatment of tumors. Tumor metastasis may be inhibited or prevented by inhibiting the adhesion of circulating cancer cells. The substances, compounds, etc. of the invention may be especially useful in the treatment of various forms of neoplasia such as leukemias, lymphomas, melanomas, adenomas, sarcomas, and carcinomas of solid tissues in patients. In particular the composition may be used for treating malignant melanoma, pancreatic cancer, cervico-uterine cancer, cancer of the liver, kidney, stomach, lung, rectum, breast, bowel, gastric, thyroid, neck, cervix, salivary gland, bile duct, pelvis, mediastinum, urethra, bronchogenic, bladder, esophagus and colon, and Kaposi's Sarcoma which is a form of cancer associated with HIV-infected patients with Acquired Immune Deficiency Syndrome (AIDS). The substances etc. are particularly useful in the prevention and treatment of tumors of the immune system and thymus and the metastases derived from these tumors.

A substance or compound identified in accordance with the methods described herein, antibodies, polypeptides, or nucleic acid molecules of the invention may be used to modulate T-cell activation and immunodeficiency due to the Wiskott-Aldrich syndrome or AIDS, or to stimulate hematopoietic progenitor cell growth, and/or confer protection against chemotherapy and radiation therapy in a subject.

Accordingly, the substances, antibodies, and compounds may be formulated into pharmaceutical compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By biologically compatible form suitable for administration *in vivo* is meant a form of the substance to be administered in which

any toxic effects are outweighed by the therapeutic effects. The substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention is defined as an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions that may inactivate the compound.

The compositions described herein can be prepared by methods known per se for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the

compositions include, albeit not exclusively, solutions of the substances or compounds in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of an inhibitor of a polypeptide of the invention, such labeling would include amount, frequency, and method of administration.

The nucleic acids encoding C2GnT3 polypeptides or any fragment thereof, or antisense sequences may be used for therapeutic purposes. Antisense to a nucleic acid molecule encoding a polypeptide of the invention may be used in situations to block the synthesis of the polypeptide. In particular, cells may be transformed with sequences complementary to nucleic acid molecules encoding C2GnT3 polypeptide. Thus, antisense sequences may be used to modulate C2GnT3 activity or to achieve regulation of gene function. Sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or regulatory regions of sequences encoding a polypeptide of the invention.

Expression vectors may be derived from retroviruses, adenoviruses, herpes or vaccinia viruses or from various bacterial plasmids for delivery of nucleic acid sequences to the target organ, tissue, or cells. Vectors that express antisense nucleic acid sequences of C2GnT3 polypeptide can be constructed using techniques well known to those skilled in the art (see for example, Sambrook, Fritsch, Maniatis, Molecular Cloning, A Laboratory Man-

ual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y).

Genes encoding C2CnT3 polypeptide can be turned off by transforming a cell or tissue with expression vectors
5 that express high levels of a nucleic acid molecule or fragment thereof which encodes a polypeptide of the invention. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even if they do not integrate into the DNA, the vectors
10 may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases. Transient expression may last for extended periods of time (e.g. a month or more) with a non-replicating vector or if appropriate replication elements are part of the vector system.

15 Modification of gene expression may be achieved by designing antisense molecules, DNA, RNA, or PNA, to the control regions of a C2GnT3 polypeptide gene i.e. the promoters, enhancers, and introns. Preferably the antisense molecules are oligonucleotides derived from the
20 transcription initiation site (e.g. between positions -10 and +10 from the start site). Inhibition can also be achieved by using triple-helix base-pairing techniques. Triple helix pairing causes inhibition of the ability of the double helix to open sufficiently for the binding of
25 polymerases, transcription factors, or regulatory molecules (see Gee J.E. et al (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.).

Ribozymes, enzymatic RNA molecules, may be used to catalyze the specific cleavage of RNA. Ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, hammerhead motif ri-

30

bozyme molecules may be engineered that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding a polypeptide of the invention.

Specific ribosome cleavage sites within any RNA target
5 may be initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the cleavage site of the target gene may be
10 evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

15 Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population)
20 statistics. The therapeutic index is the dose ratio of therapeutic to toxic effects and it can be expressed as the ED₅₀/LD₅₀ ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred.

25 The invention also provides methods for studying the function of a C2GnT3 polypeptide. Cells, tissues, and non-human animals lacking in C2GnT3 expression or partially lacking in C2GnT3 expression may be developed using recombinant expression vectors of the invention having
30 specific deletion or insertion mutations in a C2GnT3 gene. A recombinant expression vector may be used to inactivate or alter the endogenous gene by homologous re-

combination, and thereby create a C2GnT3 deficient cell, tissue or animal.

Null alleles may be generated in cells, such as embryonic stem cells by deletion mutation. A recombinant C2GnT3
5 gene may also be engineered to contain an insertion mutation which inactivates C2GnT3. Such a construct may then be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, electroporation, injection etc. Cells lacking an intact C2GnT3 gene
10 may then be identified, for example by Southern blotting, Northern Blotting or by assaying for expression of a polypeptide of the invention using the methods described herein. Such cells may then be used to generate transgenic non-human animals deficient in C2GnT3. Germline
15 transmission of the mutation may be achieved, for example, by aggregating the embryonic stem cells with early stage embryos, such as 8 cell embryos, *in vitro*; transferring the resulting blastocysts into recipient females and; generating germline transmission of the resulting
20 aggregation chimeras. Such a mutant animal may be used to define specific cell populations, developmental patterns and *in vivo* processes, normally dependent on C2GnT3 expression.

The invention thus provides a transgenic non-human mammal
25 all of whose germ cells and somatic cells contain a recombinant expression vector that inactivates or alters a gene encoding a C2GnT3 polypeptide. Further the invention provides a transgenic non-human mammal, which does not express a C2GnT3 polypeptide of the invention.

30 A transgenic non-human animal includes but is not limited to mouse, rat, rabbit, sheep, hamster, guinea pig, micro-pig, pig, dog, cat, goat, and non-human primate, preferably mouse.

The invention also provides a transgenic non-human animal assay system which provides a model system for testing for an agent that reduces or inhibits a pathology associated with a C2GnT3 polypeptide comprising: (a) administering the agent to a transgenic non-human animal of the invention; and (b) determining whether said agent reduces or inhibits the pathology in the transgenic non-human animal relative to a transgenic non-human animal of step (a) to which the agent has not been administered.

10 The agent may be useful to treat the disorders and conditions discussed herein. The agents may also be incorporated in a pharmaceutical composition as described herein.

15 A polypeptide of the invention may be used to support the survival, growth, migration, and/or differentiation of cells expressing the polypeptide. Thus, a polypeptide of the invention may be used as a supplement to support, for example cells in culture.

Methods to Prepare Oligosaccharides

20 The invention relates to a method for preparing an oligosaccharide comprising contacting a reaction mixture comprising an activated donor substrate e.g. GlcNAc, and an acceptor substrate in the presence of a polypeptide of the invention.

25 Examples of acceptor substrates for use in the method for preparing an oligosaccharide are a saccharide, oligosaccharides, polysaccharides, glycopeptides, glycopolypeptides, or glycolipids which are either synthetic with linkers at the reducing end or naturally occurring structures, for example, asialo-agalacto-fetuin glycopeptide.
30 The activated donor substrate is preferably GlcNAc which

may be part of a nucleotide-sugar, a dolichol-phosphate-sugar, or dolichol-pyrophosphate-oligosaccharide.

In an embodiment of the invention, the oligosaccharides are prepared on a carrier that is non-toxic to a mammal, in particular a human such as a lipid isoprenoid or poly-isoprenoid alcohol. An example of a suitable carrier is dolichol phosphate. The oligosaccharide may be attached to a carrier via a labile bond allowing for chemical removal of the oligosaccharide from the lipid carrier. In the alternative, the oligosaccharide transferase may be used to transfer the oligosaccharide from a lipid carrier to a polypeptide.

The following examples are intended to further illustrate the invention without limiting its scope.

EXAMPLE 1

A: Identification of cDNA homologous to C2GnT3 by analysis of GSS database sequence information.

Database searches were performed with the coding sequence of the human C2/4GnT (C2GnT2) sequence using the BLASTn and tBLASTn algorithms against the GSS database at The National Center for Biotechnology Information, USA. The BLASTn algorithm was used to identify GSSs representing the query gene (identities of $\geq 95\%$), whereas tBLASTn was used to identify non-identical, but similar GSS sequences. GSSs with 50-90% nucleotide sequence identity were regarded as different from the query sequence. Composites of the sequence information for two GSSs were compiled and analysed for sequence similarity to human C2/4GnT (C2GnT2).

B: Cloning and sequencing of C2GnT3

A GSS clone CIT-HSP-2288B17.TF (GSS GenBank accession number AQ005888), derived from a putative homologue to C2/4GnT (C2GnT2), was obtained from Research Genetics Inc., USA. Sequencing of this clone revealed a partial open reading frame with significant sequence similarity to C2/4GnT (C2GnT2). The coding region of human C2GnT-L (C2GnT1), C2/4GnT (C2GnT2) and a bovine homologue was previously found to be organized in one exon ((22), (15)).

10 Since the 3' sequence available from the C2GnT3 GSS was incomplete but likely to be located in the single exon, the missing 3' portion of the open reading frame was obtained by sequencing a genomic P1 clone. The P1 clone was obtained from a human foreskin genomic P1 library (DuPont Merck Pharmaceutical Co. Human Foreskin Fibroblast P1 Li-

15 brary) by screening with the primer pair TSHC96 (5'-GGTTTCACCGTCTCCAACATA-3', SEQ ID NO: 3) and TSHC101 (5'-TCGTAAGGCACCTGATACTT -3', SEQ ID NO: 6). One genomic clone for C2GnT3, GS22597 #844/B1 was obtained

20 from Genome Systems Inc., USA. DNA from P1 phage was prepared as recommended by Genome Systems Inc. The entire coding sequence of the C2GnT3 gene was represented in the clone and sequenced in full using automated sequencing (ABI377, Perkin-Elmer). Confirmatory sequencing was performed on a cDNA clone obtained by PCR (30 cycles at 95°C for 10 sec; 55°C for 15 sec and 68°C for 2 min 30 sec) on cDNA from human thymus poly A-mRNA with the sense primer TSHC 99 (5'- CGAGGATCCAGAATGAAGATATTCAAATGTTA-3', SEQ ID NO: 4) and the anti-sense primer TSHC121

25 (5'-AGCGAATTCTTACTATCATGATGTGGTAGTG-3', SEQ ID NO: 9).

30 The composite sequence contained an open reading frame of 1359 base pairs encoding a putative protein of 453 amino acids with type II domain structure predicted by the TMpred-algorithm at the Swiss Institute for Experimental

Cancer Research (ISREC).

EXAMPLE 2

A: Expression of C2GnT3 in Sf9 cells

5 An expression construct designed to encode amino acid residues 39-453 of C2GnT3 was prepared by PCR using P1 DNA, and the primer pair TSHC100 (5'-CGAGGATCCGCAAAAAGACATTTACTTGGTT -3', SEQ ID NO: 5) and TSHC121 (5'-AGCGAATTCTTACTATCATGATGTGGTAGTG-
10 3', SEQ ID NO: 9) with *Bam*HI and *Eco*RI restriction sites, respectively (Fig. 2). The PCR product was cloned between the *Bam*HI and *Eco*RI sites of pAcGP67A (PharMingen), and the insert was fully sequenced. pAcGP67-C2GnT3-sol was co-transfected with Baculo-Gold™ DNA (PharMingen) as de-
15 scribed previously (23). Recombinant Baculo-viruses were obtained after two successive amplifications in Sf9 cells grown in serum-containing medium, and titers of virus were estimated by titration in 24-well plates with monitoring of enzyme activities. Transfection of Sf9-cells
20 with pAcGP67-C2GnT3-sol resulted in marked increase in GlcNAc-transferase activity compared to uninfected cells or cells infected with a control construct.

B: Analysis of C2GnT3 activity

Standard assays were performed using culture supernatant
25 from infected cells in 50 µl reaction mixtures containing 100 mM MES (pH 6.5), 0.1% Nonidet P-40, 150 µM UDP-[¹⁴C]-GlcNAc (2,000 cpm/nmol) (Amersham Pharmacia Biotech), and the indicated concentrations of acceptor substrates (Sigma and Toronto Research Laboratories Ltd., see Table
30 I for structures). Reaction products were quantified by chromatography on Dowex AG1-X8.

EXAMPLE 3***Restricted organ expression pattern of C2GnT3***

A human RNA master blot (CLONTECH) was used for expression analysis. The cDNA-fragment of soluble C2GnT3 was
5 used as a probe for hybridization. The probe was random primer-labeled using [$\alpha^{32}\text{P}$]dATP and the Strip-EZ DNA labeling kit (Ambion). The membrane was probed for 6h at 65°C following the protocol of the manufacturer (CLONTECH) and washed five times for 20 min each at 65 °C
10 with 2 × SSC, 1% SDS and twice for 20 min each at 55 °C with 0.1 × SSC, 0.5 % SDS. A human multiple tissue Northern blot MTN II (CLONTECH), was probed as described (24), and washed twice for 10 min each at room temperature with 2 × SSC, 0.1% SDS; twice for 10 min each at 55 °C with 1
15 × SSC, 0.1 % SDS; and once for 10 min with 0.1 × SSC, 0.1 % SDS at 55 °C.

EXAMPLE 4***Analysis of C2GnT3 gene expression in peripheral blood mononuclear cells***

20 PCR analysis of C2GnT3 expression in resting and activated human blood cell fractions was performed using the primer pair TSHC118 (5'-GAGTCAGTGTGGAATTGAATAC-3', SEQ ID NO: 7) and TSHC126 (5'-CAACAGTCTCCTCAACCCTG-3', SEQ ID NO: 11). PCR amplifications with primers specific for hu-
25 man C2GnT3 (C2GnT3) or GAPDH (G3PDH, supplied by the manufacturer) were performed on a normalized human blood cell cDNA panel (MTC from CLONTECH) for 31 cycles. Expression of C2GnT3 transcript was detected in all peripheral blood mononuclear cell (PBMC) fractions with particularly high levels of expression in CD4 and CD8 posi-
30 tive T-lymphocytes (Figure 4).

EXAMPLE 5***Analysis of DNA polymorphism of the C2GnT3 gene***

Primer pairs such as TSHC123 (5'-GGGCAGCATTTGCCTAGTATG-3',
SEQ ID NO: 10) and TSHC119 (5'-GATCTCTGATTTGGCTCAGTG-3',
5 SEQ ID NO: 8) as described in Figure 5 have been used for
PCR amplification of individual sequences of the coding
exon. Each PCR product was subcloned and the sequence of
10 clones containing the appropriate insert was determined
assuring that both alleles of each individual are charac-
10 terized.

From the foregoing it will be evident that, although spe-
cific embodiments of the invention have been described
herein for purposes of illustration, various modifications
may be made without deviating from the spirit and scope of
15 the invention.

REFERENCES

1. Clausen, H. and Bennett, E.P. A family of UDP-
GalNAc: polypeptide N-acetylgalactosaminyltrans-
ferases control the initiation of mucin-type O-
20 linked glycosylation. Glycobiology 6: 635-646,
1996.
2. Piller, F., Piller, V., Fox, R.I., and Fukuda, M.
Human T-lymphocyte activation is associated with
changes in O-glycan biosynthesis. J. Biol. Chem.
25 263: 15146-15150, 1988.
3. Yang, J.M., Byrd, J.C., Siddiki, B.B., Chung,
Y.S., Okuno, M., Sowa, M., Kim, Y.S., Matta,
K.L., and Brockhausen, I. Alterations of O-glycan

biosynthesis in human colon cancer tissues. *Glycobiology* 4: 873-884, 1994.

4. Yousefi, S., Higgins, E., Daoling, Z., Pollex-Kruger, A., Hindsgaul, O., and Dennis, J.W. Increased UDP-GlcNAc:Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta-1, 6- N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis. *J. Biol. Chem.* 266: 1772-1782, 1991.
5. Fukuda, M. Possible roles of tumor-associated carbohydrate antigens. *Cancer Res.* 56: 2237-2244, 1996.
6. Brockhausen, I., Yang, J.M., Burchell, J., Whitehouse, C., and Taylor-Papadimitriou, J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. *Eur. J. Biochem.* 233: 607-617, 1995.
7. Brockhausen, I., Kuhns, W., Schachter, H., Matta, K.L., Sutherland, D.R., and Baker, M.A. Biosynthesis of O-glycans in leukocytes from normal donors and from patients with leukemia: increase in O-glycan core 2 UDP-GlcNAc:Gal beta 3 GalNAc alpha-R (GlcNAc to GalNAc) beta(1-6)-N-acetylglucosaminyltransferase in leukemic cells. *Cancer Res.* 51: 1257-1263, 1991.
8. Higgins, E.A., Siminovitch, K.A., Zhuang, D.L., Brockhausen, I., and Dennis, J.W. Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome. *J. Biol. Chem.* 266: 6280-6290, 1991.

9. Saitoh, O., Piller, F., Fox, R.I., and Fukuda, M. T-lymphocytic leukemia expresses complex, branched O-linked oligosaccharides on a major sialoglycoprotein, leukosialin. Blood 77: 1491-1499,
5 1991.
10. Springer, G.F. T and Tn, general carcinoma auto-antigens. Science 224: 1198-1206, 1984.
11. Kumar, R., Camphausen, R.T., Sullivan, F.X., and Cumming, D.A. Core2 beta-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin. Blood 88: 3872-3879, 1996.
10
12. Williams, D. and Schachter, H. Mucin synthesis. I. Detection in canine submaxillary glands of an N- acetylglucosaminyltransferase which acts on
15 mucin substrates. J. Biol. Chem. 255: 11247-11252, 1980.
13. Bierhuizen, M.F. and Fukuda, M. Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 89: 9326-9330, 1992.
20
14. Schwientek, T., Yeh, J.C., Levery, S.B., Keck, B., Merkx, G., van Kessel, A.G., Fukuda, M., and Clausen, H. Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. J. Biol. Chem. 275: 11106-
25 11113, 2000.
30

15. Schwientek, T., Nomoto, M., Lavery, S.B., Merkx, G., van Kessel, A.G., Bennett, E.P., Hollingsworth, M.A., and Clausen, H. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. J. Biol. Chem. 274: 4504-4512, 1999.
16. Yeh, J.C., Ong, E., and Fukuda, M. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. J. Biol. Chem. 274: 3215-3221, 1999.
17. Baum, L.G., Pang, M., Perillo, N.L., Wu, T., Delegeane, A., Uittenbogaart, C.H., Fukuda, M., and Seilhamer, J.J. Human thymic epithelial cells express an endogenous lectin, galectin-1, which binds to core 2 O-glycans on thymocytes and T lymphoblastoid cells. J. Exp. Med. 181: 877-887, 1995.
18. Perillo, N.L., Marcus, M.E., and Baum, L.G. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 76: 402-412, 1998.
19. Perillo, N.L., Pace, K.E., Seilhamer, J.J., and Baum, L.G. Apoptosis of T cells mediated by galectin-1. Nature 378: 736-739, 1995.
20. Devereux, J., Haeberli, P., and Smithies, O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 12: 387-395, 1984

21. Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 1990, Oct.5., 215: 403-410,
- 5 22. Bierhuizen, M.F., Maemura, K., Kudo, S., and Fukushima, M. Genomic organization of core 2 and I branching beta-1,6-N- acetylglucosaminyltransferases. Implication for evolution of the beta-1,6-N-acetylglucosaminyltransferase gene family. Glycobiology 5: 417-425, 1995.
- 10 23. Almeida, R., Amado, M., David, L., Levery, S.B., Holmes, E.H., Merkx, G., van Kessel, A.G., Rygaard, E., Hassan, H., Bennett, E., and Clausen, H. A family of human beta4-galactosyltransferases. Cloning and expression of two novel UDP-galactose: beta-N-acetylglucosamine beta1,4-galactosyltransferases, beta4Gal-T2 and beta4Gal-T3. J. Biol. Chem. 272: 31979-31991, 1997.
- 15 24. Bennett, E.P., Hassan, H., and Clausen, H. cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D- galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-T3. J. Biol. Chem. 271: 17006-17012, 1996.
- 20 25. Wandall, H.H., Hassan, H., Mirgorodskaya, E., Kristensen, A.K., Roepstorff, P., Bennett, E.P., Nielsen, P.A., Hollingsworth, M.A., Burchell, J., Taylor-Papadimitriou, J., and Clausen, H. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. J. Biol. Chem. 272: 23503-23514, 1997.
- 25 30

26. Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc. 103: 3185-3191. 1981.
 27. Yoo, Y., Rote, K., and Rechsteiner, M. Synthesis of peptides as cloned ubiquitin extensions. J. Biol. Chem. 264: 17078-17083, 1989.
- 5

63a

SEQUENCE LISTING

<110> Glycozym ApS.

<120> UDP-N-Acetylglucosamine: Galactose-beta1,3-N-Acetylgalactosamine-alpha-R/(GlcNAc to GalNAc) beta1,6-N-Acetylglucosaminyltransferase, C2GnT3

<130> 2463-474CA FC/gc

<150> PCT/DK00/00469

<151> 2000-08-24

<150> 60/150,488

<151> 1999-08-24

<160> 17

<170> PatentIn Ver. 2.1

<210> 1

<211> 1362

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1359)

<223> The gene of C2GnT3

<400> 1

atg aag ata ttc aaa tgt tat ttt aaa cat acc cta cag cag aaa gtt	48
Met Lys Ile Phe Lys Cys Tyr Phe Lys His Thr Leu Gln Gln Lys Val	
1 5 10 15	
ttc atc ctg ttt tta acc cta tgg ctg ctc tct ttg tta aag ctt cta	96
Phe Ile Leu Phe Leu Thr Leu Trp Leu Leu Ser Leu Leu Lys Leu Leu	
20 25 30	
aat gtg aga cga ctc ttt ccg caa aaa gac att tac ttg gtt gag tac	144
Asn Val Arg Arg Leu Phe Pro Gln Lys Asp Ile Tyr Leu Val Glu Tyr	
35 40 45	
tcc cta agt acc tcg cct ttt gta aga aac aga tac act cat gtt aag	192
Ser Leu Ser Thr Ser Pro Phe Val Arg Asn Arg Tyr Thr His Val Lys	
50 55 60	
gat gaa gtc agg tat gaa gtt aac tgt tcg ggt atc tat gaa cag gag	240
Asp Glu Val Arg Tyr Glu Val Asn Cys Ser Gly Ile Tyr Glu Gln Glu	
65 70 75 80	
cct ttg gaa att gga aag agt ctg gaa ata aga aga agg gac atc att	288
Pro Leu Glu Ile Gly Lys Ser Leu Glu Ile Arg Arg Arg Asp Ile Ile	
85 90 95	

63b

gac ttg gag gat gat gat gtt gtg gca atg acc agt gat tgt gac att	336
Asp Leu Glu Asp Asp Asp Val Val Ala Met Thr Ser Asp Cys Asp Ile	
100 105 110	
tat cag act cta aga ggt tat gct caa aag ctt gtc tca aag gag gag	384
Tyr Gln Thr Leu Arg Gly Tyr Ala Gln Lys Leu Val Ser Lys Glu Glu	
115 120 125	
aaa agc ttc cca ata gcc tat tct ttg gtt gtc cac aaa gat gca att	432
Lys Ser Phe Pro Ile Ala Tyr Ser Leu Val Val His Lys Asp Ala Ile	
130 135 140	
atg gtt gaa agg ctt atc cat gct ata tac aac cag cac aat att tac	480
Met Val Glu Arg Leu Ile His Ala Ile Tyr Asn Gln His Asn Ile Tyr	
145 150 155 160	
tgc atc cat tat gat cgt aag gca cct gat acc ttc aaa gtt gcc atg	528
Cys Ile His Tyr Asp Arg Lys Ala Pro Asp Thr Phe Lys Val Ala Met	
165 170 175	
aac aat tta gct aag tgc ttc tcc aat att ttc att gct tcc aaa tta	576
Asn Asn Leu Ala Lys Cys Phe Ser Asn Ile Phe Ile Ala Ser Lys Leu	
180 185 190	
gag gct gtg gaa tat gcc cac att tcc aga ctc cag gct gat tta aat	624
Glu Ala Val Glu Tyr Ala His Ile Ser Arg Leu Gln Ala Asp Leu Asn	
195 200 205	
tgc ttg tcg gac ctt ctg aag tct tca atc cag tgg aaa tat gtt atc	672
Cys Leu Ser Asp Leu Leu Lys Ser Ser Ile Gln Trp Lys Tyr Val Ile	
210 215 220	
aac ttg tgt ggg caa gat ttt ccc ctg aag tca aat ttt gaa ttg gtg	720
Asn Leu Cys Gly Gln Asp Phe Pro Leu Lys Ser Asn Phe Glu Leu Val	
225 230 235 240	
tca gag ttg aaa aaa ctc aat gga gca aat atg ttg gag acg gtg aaa	768
Ser Glu Leu Lys Lys Leu Asn Gly Ala Asn Met Leu Glu Thr Val Lys	
245 250 255	
ccc cca aac agt aaa ttg gaa aga ttc act tac cat cat gaa ctt aga	816
Pro Pro Asn Ser Lys Leu Glu Arg Phe Thr Tyr His His Glu Leu Arg	
260 265 270	
cgg gtg cct tat gaa tat gtg aag cta cca ata agg aca aac atc tcc	864
Arg Val Pro Tyr Glu Tyr Val Lys Leu Pro Ile Arg Thr Asn Ile Ser	
275 280 285	
aag gaa gca ccc ccc cat aac att cag ata ttt gtt ggc agt gct tat	912
Lys Glu Ala Pro Pro His Asn Ile Gln Ile Phe Val Gly Ser Ala Tyr	
290 295 300	
ttt gtt tta agt caa gca ttt gtt aaa tat att ttc aac aac tcc atc	960
Phe Val Leu Ser Gln Ala Phe Val Lys Tyr Ile Phe Asn Asn Ser Ile	
305 310 315 320	

63c

gtt caa gac ttt ttt gcc tgg tct aaa gac aca tac tct cct gat gag 1008
 Val Gln Asp Phe Phe Ala Trp Ser Lys Asp Thr Tyr Ser Pro Asp Glu
 325 330 335

cac ttt tgg gct acc ttg att cgg gtt cca gga ata cct ggg gag att 1056
 His Phe Trp Ala Thr Leu Ile Arg Val Pro Gly Ile Pro Gly Glu Ile
 340 345 350

tcc aga tca gcc cag gat gtg tct gat ctg cag agt aag act cgc ctt 1104
 Ser Arg Ser Ala Gln Asp Val Ser Asp Leu Gln Ser Lys Thr Arg Leu
 355 360 365

gtc aag tgg aat tac tat gaa ggc ttt ttc tat ccc agt tgt act gga 1152
 Val Lys Trp Asn Tyr Tyr Glu Gly Phe Phe Tyr Pro Ser Cys Thr Gly
 370 375 380

tct cac ctt cga agc gtg tgt att tat gga gct gca gaa tta agg tgg 1200
 Ser His Leu Arg Ser Val Cys Ile Tyr Gly Ala Ala Glu Leu Arg Trp
 385 390 395 400

ctt atc aaa gat gga cat tgg ttt gct aat aaa ttt gat tct aag gtg 1248
 Leu Ile Lys Asp Gly His Trp Phe Ala Asn Lys Phe Asp Ser Lys Val
 405 410 415

gac cct atc ttg att aaa tgc ttg gca gaa aag ctt gaa gaa cag cag 1296
 Asp Pro Ile Leu Ile Lys Cys Leu Ala Glu Lys Leu Glu Glu Gln Gln
 420 425 430

aga gac tgg atc act ttg ccc tca gaa aag tta ttt atg gat aga aat 1344
 Arg Asp Trp Ile Thr Leu Pro Ser Glu Lys Leu Phe Met Asp Arg Asn
 435 440 445

ctc act acc aca tca tga 1362
 Leu Thr Thr Thr Ser
 450

<210> 2
 <211> 453
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Lys Ile Phe Lys Cys Tyr Phe Lys His Thr Leu Gln Gln Lys Val
 1 5 10 15

Phe Ile Leu Phe Leu Thr Leu Trp Leu Leu Ser Leu Leu Lys Leu Leu
 20 25 30

Asn Val Arg Arg Leu Phe Pro Gln Lys Asp Ile Tyr Leu Val Glu Tyr
 35 40 45

Ser Leu Ser Thr Ser Pro Phe Val Arg Asn Arg Tyr Thr His Val Lys
 50 55 60

63d

Asp	Glu	Val	Arg	Tyr	Glu	Val	Asn	Cys	Ser	Gly	Ile	Tyr	Glu	Gln	Glu	65	70	75	80
Pro	Leu	Glu	Ile	Gly	Lys	Ser	Leu	Glu	Ile	Arg	Arg	Arg	Asp	Ile	Ile		85	90	95
Asp	Leu	Glu	Asp	Asp	Asp	Val	Val	Ala	Met	Thr	Ser	Asp	Cys	Asp	Ile	100	105	110	
Tyr	Gln	Thr	Leu	Arg	Gly	Tyr	Ala	Gln	Lys	Leu	Val	Ser	Lys	Glu	Glu	115	120	125	
Lys	Ser	Phe	Pro	Ile	Ala	Tyr	Ser	Leu	Val	Val	His	Lys	Asp	Ala	Ile	130	135	140	
Met	Val	Glu	Arg	Leu	Ile	His	Ala	Ile	Tyr	Asn	Gln	His	Asn	Ile	Tyr	145	150	155	160
Cys	Ile	His	Tyr	Asp	Arg	Lys	Ala	Pro	Asp	Thr	Phe	Lys	Val	Ala	Met	165	170	175	
Asn	Asn	Leu	Ala	Lys	Cys	Phe	Ser	Asn	Ile	Phe	Ile	Ala	Ser	Lys	Leu	180	185	190	
Glu	Ala	Val	Glu	Tyr	Ala	His	Ile	Ser	Arg	Leu	Gln	Ala	Asp	Leu	Asn	195	200	205	
Cys	Leu	Ser	Asp	Leu	Leu	Lys	Ser	Ser	Ile	Gln	Trp	Lys	Tyr	Val	Ile	210	215	220	
Asn	Leu	Cys	Gly	Gln	Asp	Phe	Pro	Leu	Lys	Ser	Asn	Phe	Glu	Leu	Val	225	230	235	240
Ser	Glu	Leu	Lys	Lys	Leu	Asn	Gly	Ala	Asn	Met	Leu	Glu	Thr	Val	Lys	245	250	255	
Pro	Pro	Asn	Ser	Lys	Leu	Glu	Arg	Phe	Thr	Tyr	His	His	Glu	Leu	Arg	260	265	270	
Arg	Val	Pro	Tyr	Glu	Tyr	Val	Lys	Leu	Pro	Ile	Arg	Thr	Asn	Ile	Ser	275	280	285	
Lys	Glu	Ala	Pro	Pro	His	Asn	Ile	Gln	Ile	Phe	Val	Gly	Ser	Ala	Tyr	290	295	300	
Phe	Val	Leu	Ser	Gln	Ala	Phe	Val	Lys	Tyr	Ile	Phe	Asn	Asn	Ser	Ile	305	310	315	320
Val	Gln	Asp	Phe	Phe	Ala	Trp	Ser	Lys	Asp	Thr	Tyr	Ser	Pro	Asp	Glu	325	330	335	
His	Phe	Trp	Ala	Thr	Leu	Ile	Arg	Val	Pro	Gly	Ile	Pro	Gly	Glu	Ile	340	345	350	
Ser	Arg	Ser	Ala	Gln	Asp	Val	Ser	Asp	Leu	Gln	Ser	Lys	Thr	Arg	Leu	355	360	365	

63e

Val Lys Trp Asn Tyr Tyr Glu Gly Phe Phe Tyr Pro Ser Cys Thr Gly
 370 375 380

Ser His Leu Arg Ser Val Cys Ile Tyr Gly Ala Ala Glu Leu Arg Trp
 385 390 395 400

Leu Ile Lys Asp Gly His Trp Phe Ala Asn Lys Phe Asp Ser Lys Val
 405 410 415

Asp Pro Ile Leu Ile Lys Cys Leu Ala Glu Lys Leu Glu Glu Gln Gln
 420 425 430

Arg Asp Trp Ile Thr Leu Pro Ser Glu Lys Leu Phe Met Asp Arg Asn
 435 440 445

Leu Thr Thr Thr Ser
 450

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: a primer named
 TSHC96

<400> 3
 ggtttcaccg tctccaacat a

21

<210> 4
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: a primer named
 TSHC99

<400> 4
 cgaggatcca gaatgaagat attcaaattgt ta

32

<210> 5
 <211> 31
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: a primer named
 TSHC100

63f

<400> 5
cgaggatccg caaaaagaca ttacttggt t 31

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: a primer named
TSHC101

<400> 6
tcgtaaggca cctgatactt 20

<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: a primer named
TSHC118

<400> 7
gagtcagtgt ggaattgaat ac 22

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: a primer named
TSHC119

<400> 8
gatctctgat ttggctcagt g 21

<210> 9
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: a primer named
TSHC121

63g

<400> 9
 agcgaattct tactatcatg atgtggtagt g 31

<210> 10
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: a primer named
 TSHC123

<400> 10
 gggcagcatt tgcctagtat g 21

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: a primer named
 TSHC126

<400> 11
 caacagtctc ctcaaccctg 20

<210> 12
 <211> 1287
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)..(1284)
 <223> The gene of C2GnT1

<400> 12
 atg ctg agg acg ttg ctg cga agg aga ctt ttt tct tat ccc acc aaa 48
 Met Leu Arg Thr Leu Leu Arg Arg Arg Leu Phe Ser Tyr Pro Thr Lys
 1 5 10 15

tac tac ttt atg gtt ctt gtt tta tcc cta atc acc ttc tcc gtt tta 96
 Tyr Tyr Phe Met Val Leu Val Leu Ser Leu Ile Thr Phe Ser Val Leu
 20 25 30

agg att cat caa aag cct gaa ttt gta agt gtc aga cac ttg gag ctt 144
 Arg Ile His Gln Lys Pro Glu Phe Val Ser Val Arg His Leu Glu Leu
 35 40 45

63h

gct ggg gag aat cct agt agt gat att aat tgc acc aaa gtt tta cag	192
Ala Gly Glu Asn Pro Ser Ser Asp Ile Asn Cys Thr Lys Val Leu Gln	
50 55 60	
ggg gat gta aat gaa atc caa aag gta aag ctt gag atc cta aca gtg	240
Gly Asp Val Asn Glu Ile Gln Lys Val Lys Leu Glu Ile Leu Thr Val	
65 70 75 80	
aaa ttt aaa aag cgc cct cgg tgg aca cct gac gac tat ata aac atg	288
Lys Phe Lys Lys Arg Pro Arg Trp Thr Pro Asp Asp Tyr Ile Asn Met	
85 90 95	
acc agt gac tgt tct tct ttc atc aag aga cgc aaa tat att gta gaa	336
Thr Ser Asp Cys Ser Ser Phe Ile Lys Arg Arg Lys Tyr Ile Val Glu	
100 105 110	
ccc ctt agt aaa gaa gag gcg gag ttt cca ata gca tat tct ata gtg	384
Pro Leu Ser Lys Glu Glu Ala Glu Phe Pro Ile Ala Tyr Ser Ile Val	
115 120 125	
gtt cat cac aag att gaa atg ctt gac agg ctg ctg agg gcc atc tat	432
Val His His Lys Ile Glu Met Leu Asp Arg Leu Leu Arg Ala Ile Tyr	
130 135 140	
atg cct cag aat ttc tat tgc gtt cat gtg gac aca aaa tcc gag gat	480
Met Pro Gln Asn Phe Tyr Cys Val His Val Asp Thr Lys Ser Glu Asp	
145 150 155 160	
tcc tat tta gct gca gtg atg ggc atc gct tcc tgt ttt agt aat gtc	528
Ser Tyr Leu Ala Ala Val Met Gly Ile Ala Ser Cys Phe Ser Asn Val	
165 170 175	
ttt gtg gcc agc cga ttg gag agt gtg gtt tat gca tcg tgg agc cgg	576
Phe Val Ala Ser Arg Leu Glu Ser Val Val Tyr Ala Ser Trp Ser Arg	
180 185 190	
gtt cag gct gac ctc aac tgc atg aag gat ctc tat gca atg agt gca	624
Val Gln Ala Asp Leu Asn Cys Met Lys Asp Leu Tyr Ala Met Ser Ala	
195 200 205	
aac tgg aag tac ttg ata aat ctt tgt ggt atg gat ttt ccc att aaa	672
Asn Trp Lys Tyr Leu Ile Asn Leu Cys Gly Met Asp Phe Pro Ile Lys	
210 215 220	
acc aac cta gaa att gtc agg aag ctc aag ttg tta atg gga gaa aac	720
Thr Asn Leu Glu Ile Val Arg Lys Leu Lys Leu Leu Met Gly Glu Asn	
225 230 235 240	
aac ctg gaa acg gag agg atg cca tcc cat aaa gaa gaa agg tgg aag	768
Asn Leu Glu Thr Glu Arg Met Pro Ser His Lys Glu Glu Arg Trp Lys	
245 250 255	
aag cgg tat gag gtc gtt aat gga aag ctg aca aac aca ggg act gtc	816
Lys Arg Tyr Glu Val Val Asn Gly Lys Leu Thr Asn Thr Gly Thr Val	
260 265 270	

63i

```

aaa atg ctt cct cca ctc gaa aca cct ctc ttt tct ggc agt gcc tac 864
Lys Met Leu Pro Pro Leu Glu Thr Pro Leu Phe Ser Gly Ser Ala Tyr
      275                280                285

ttc gtg gtc agt agg gag tat gtg ggg tat gta cta cag aat gaa aaa 912
Phe Val Val Ser Arg Glu Tyr Val Gly Tyr Val Leu Gln Asn Glu Lys
      290                295                300

atc caa aag ttg atg gag tgg gca caa gac aca tac agc cct gat gag 960
Ile Gln Lys Leu Met Glu Trp Ala Gln Asp Thr Tyr Ser Pro Asp Glu
305                310                315                320

tat ctc tgg gcc acc atc caa agg att cct gaa gtc ccg ggc tca ctc 1008
Tyr Leu Trp Ala Thr Ile Gln Arg Ile Pro Glu Val Pro Gly Ser Leu
      325                330                335

cct gcc agc cat aag tat gat cta tct gac atg caa gca gtt gcc agg 1056
Pro Ala Ser His Lys Tyr Asp Leu Ser Asp Met Gln Ala Val Ala Arg
      340                345                350

ttt gtc aag tgg cag tac ttt gag ggt gat gtt tcc aag ggt gct ccc 1104
Phe Val Lys Trp Gln Tyr Phe Glu Gly Asp Val Ser Lys Gly Ala Pro
      355                360                365

tac ccg ccc tgc gat gga gtc cat gtg cgc tca gtg tgc att ttc gga 1152
Tyr Pro Pro Cys Asp Gly Val His Val Arg Ser Val Cys Ile Phe Gly
      370                375                380

gct ggt gac ttg aac tgg atg ctg cgc aaa cac cac ttg ttt gcc aat 1200
Ala Gly Asp Leu Asn Trp Met Leu Arg Lys His His Leu Phe Ala Asn
385                390                395                400

aag ttt gac gtg gat gtt gac ctc ttt gcc atc cag tgt ttg gat gag 1248
Lys Phe Asp Val Asp Val Asp Leu Phe Ala Ile Gln Cys Leu Asp Glu
      405                410                415

cat ttg aga cac aaa gct ttg gag aca tta aaa cac tga 1287
His Leu Arg His Lys Ala Leu Glu Thr Leu Lys His
      420                425

```

<210> 13
 <211> 428
 <212> PRT
 <213> Homo sapiens

```

<400> 13
Met Leu Arg Thr Leu Leu Arg Arg Arg Leu Phe Ser Tyr Pro Thr Lys
  1                5                10                15

Tyr Tyr Phe Met Val Leu Val Leu Ser Leu Ile Thr Phe Ser Val Leu
      20                25                30

Arg Ile His Gln Lys Pro Glu Phe Val Ser Val Arg His Leu Glu Leu
      35                40                45

```

Ala	Gly	Glu	Asn	Pro	Ser	Ser	Asp	Ile	Asn	Cys	Thr	Lys	Val	Leu	Gln
50						55					60				
Gly	Asp	Val	Asn	Glu	Ile	Gln	Lys	Val	Lys	Leu	Glu	Ile	Leu	Thr	Val
65					70					75					80
Lys	Phe	Lys	Lys	Arg	Pro	Arg	Trp	Thr	Pro	Asp	Asp	Tyr	Ile	Asn	Met
				85					90					95	
Thr	Ser	Asp	Cys	Ser	Ser	Phe	Ile	Lys	Arg	Arg	Lys	Tyr	Ile	Val	Glu
			100					105					110		
Pro	Leu	Ser	Lys	Glu	Glu	Ala	Glu	Phe	Pro	Ile	Ala	Tyr	Ser	Ile	Val
			115				120					125			
Val	His	His	Lys	Ile	Glu	Met	Leu	Asp	Arg	Leu	Leu	Arg	Ala	Ile	Tyr
	130					135					140				
Met	Pro	Gln	Asn	Phe	Tyr	Cys	Val	His	Val	Asp	Thr	Lys	Ser	Glu	Asp
145					150					155					160
Ser	Tyr	Leu	Ala	Ala	Val	Met	Gly	Ile	Ala	Ser	Cys	Phe	Ser	Asn	Val
				165					170					175	
Phe	Val	Ala	Ser	Arg	Leu	Glu	Ser	Val	Val	Tyr	Ala	Ser	Trp	Ser	Arg
			180					185					190		
Val	Gln	Ala	Asp	Leu	Asn	Cys	Met	Lys	Asp	Leu	Tyr	Ala	Met	Ser	Ala
		195					200					205			
Asn	Trp	Lys	Tyr	Leu	Ile	Asn	Leu	Cys	Gly	Met	Asp	Phe	Pro	Ile	Lys
	210					215					220				
Thr	Asn	Leu	Glu	Ile	Val	Arg	Lys	Leu	Lys	Leu	Leu	Met	Gly	Glu	Asn
225					230					235					240
Asn	Leu	Glu	Thr	Glu	Arg	Met	Pro	Ser	His	Lys	Glu	Glu	Arg	Trp	Lys
				245					250					255	
Lys	Arg	Tyr	Glu	Val	Val	Asn	Gly	Lys	Leu	Thr	Asn	Thr	Gly	Thr	Val
			260					265					270		
Lys	Met	Leu	Pro	Pro	Leu	Glu	Thr	Pro	Leu	Phe	Ser	Gly	Ser	Ala	Tyr
		275					280					285			
Phe	Val	Val	Ser	Arg	Glu	Tyr	Val	Gly	Tyr	Val	Leu	Gln	Asn	Glu	Lys
	290					295					300				
Ile	Gln	Lys	Leu	Met	Glu	Trp	Ala	Gln	Asp	Thr	Tyr	Ser	Pro	Asp	Glu
305					310					315					320
Tyr	Leu	Trp	Ala	Thr	Ile	Gln	Arg	Ile	Pro	Glu	Val	Pro	Gly	Ser	Leu
				325					330					335	
Pro	Ala	Ser	His	Lys	Tyr	Asp	Leu	Ser	Asp	Met	Gln	Ala	Val	Ala	Arg
			340					345					350		

63k

Phe Val Lys Trp Gln Tyr Phe Glu Gly Asp Val Ser Lys Gly Ala Pro
 355 360 365

Tyr Pro Pro Cys Asp Gly Val His Val Arg Ser Val Cys Ile Phe Gly
 370 375 380

Ala Gly Asp Leu Asn Trp Met Leu Arg Lys His His Leu Phe Ala Asn
 385 390 395 400

Lys Phe Asp Val Asp Val Asp Leu Phe Ala Ile Gln Cys Leu Asp Glu
 405 410 415

His Leu Arg His Lys Ala Leu Glu Thr Leu Lys His
 420 425

<210> 14

<211> 1317

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1314)

<223> The gene of C2GnT2

<400> 14

atg gtt caa tgg aag aga ctc tgc cag ctg cat tac ttg tgg gct ctg 48
 Met Val Gln Trp Lys Arg Leu Cys Gln Leu His Tyr Leu Trp Ala Leu
 1 5 10 15

ggc tgc tat atg ctg ctg gcc act gtg gct ctg aaa ctt tct ttc agg 96
 Gly Cys Tyr Met Leu Leu Ala Thr Val Ala Leu Lys Leu Ser Phe Arg
 20 25 30

ttg aag tgt gac tct gac cac ttg ggt ctg gag tcc agg gaa tct caa 144
 Leu Lys Cys Asp Ser Asp His Leu Gly Leu Glu Ser Arg Glu Ser Gln
 35 40 45

agc cag tac tgt agg aat atc ttg tat aat ttc ctg aaa ctt cca gca 192
 Ser Gln Tyr Cys Arg Asn Ile Leu Tyr Asn Phe Leu Lys Leu Pro Ala
 50 55 60

aag agg tct atc aac tgt tca ggg gtc acc cga ggg gac caa gag gca 240
 Lys Arg Ser Ile Asn Cys Ser Gly Val Thr Arg Gly Asp Gln Glu Ala
 65 70 75 80

gtg ctt cag gct att ctg aat aac ctg gag gtc aag aag aag cga gag 288
 Val Leu Gln Ala Ile Leu Asn Asn Leu Glu Val Lys Lys Lys Arg Glu
 85 90 95

cct ttc aca gac acc cac tac ctc tcc ctc acc aga gac tgt gag cac 336
 Pro Phe Thr Asp Thr His Tyr Leu Ser Leu Thr Arg Asp Cys Glu His
 100 105 110

631

ttc aag gct gaa agg aag ttc ata cag ttc cca ctg agc aaa gaa gag	384
Phe Lys Ala Glu Arg Lys Phe Ile Gln Phe Pro Leu Ser Lys Glu Glu	
115 120 125	
gtg gag ttc cct att gca tac tct atg gtg att cat gag aag att gaa	432
Val Glu Phe Pro Ile Ala Tyr Ser Met Val Ile His Glu Lys Ile Glu	
130 135 140	
aac ttt gaa agg cta ctg cga gct gtg tat gcc cct cag aac ata tac	480
Asn Phe Glu Arg Leu Leu Arg Ala Val Tyr Ala Pro Gln Asn Ile Tyr	
145 150 155 160	
tgt gtc cat gtg gat gag aag tcc cca gaa act ttc aaa gag gcg gtc	528
Cys Val His Val Asp Glu Lys Ser Pro Glu Thr Phe Lys Glu Ala Val	
165 170 175	
aaa gca att att tct tgc ttc cca aat gtc ttc ata gcc agt aag ctg	576
Lys Ala Ile Ile Ser Cys Phe Pro Asn Val Phe Ile Ala Ser Lys Leu	
180 185 190	
gtt cgg gtg gtt tat gcc tcc tgg tcc agg gtg caa gct gac ctc aac	624
Val Arg Val Val Tyr Ala Ser Trp Ser Arg Val Gln Ala Asp Leu Asn	
195 200 205	
tgc atg gaa gac ttg ctc cag agc tca gtg ccg tgg aaa tac ttc ctg	672
Cys Met Glu Asp Leu Leu Gln Ser Ser Val Pro Trp Lys Tyr Phe Leu	
210 215 220	
aat aca tgt ggg acg gac ttt cct ata aag agc aat gca gag atg gtc	720
Asn Thr Cys Gly Thr Asp Phe Pro Ile Lys Ser Asn Ala Glu Met Val	
225 230 235 240	
cag gct ctc aag atg ttg aat ggg agg aat agc atg gag tca gag gta	768
Gln Ala Leu Lys Met Leu Asn Gly Arg Asn Ser Met Glu Ser Glu Val	
245 250 255	
cct cct aag cac aaa gaa acc cgc tgg aaa tat cac ttt gag gta gtg	816
Pro Pro Lys His Lys Glu Thr Arg Trp Lys Tyr His Phe Glu Val Val	
260 265 270	
aga gac aca tta cac cta acc aac aag aag aag gat cct ccc cct tat	864
Arg Asp Thr Leu His Leu Thr Asn Lys Lys Lys Asp Pro Pro Pro Tyr	
275 280 285	
aat tta act atg ttt aca ggg aat gcg tac att gtg gct tcc cga gat	912
Asn Leu Thr Met Phe Thr Gly Asn Ala Tyr Ile Val Ala Ser Arg Asp	
290 295 300	
ttc gtc caa cat gtt ttg aag aac cct aaa tcc caa caa ctg att gaa	960
Phe Val Gln His Val Leu Lys Asn Pro Lys Ser Gln Gln Leu Ile Glu	
305 310 315 320	
tgg gta aaa gac act tat agc cca gat gaa cac ctc tgg gcc acc ctt	1008
Trp Val Lys Asp Thr Tyr Ser Pro Asp Glu His Leu Trp Ala Thr Leu	
325 330 335	

63m

cag cgt gca cgg tgg atg cct ggc tct gtt ccc aac cac ccc aag tac 1056
 Gln Arg Ala Arg Trp Met Pro Gly Ser Val Pro Asn His Pro Lys Tyr
 340 345 350

gac atc tca gac atg act tct att gcc agg ctg gtc aag tgg cag ggt 1104
 Asp Ile Ser Asp Met Thr Ser Ile Ala Arg Leu Val Lys Trp Gln Gly
 355 360 365

cat gag gga gac atc gat aag ggt gct cct tat gct ccc tgc tct gga 1152
 His Glu Gly Asp Ile Asp Lys Gly Ala Pro Tyr Ala Pro Cys Ser Gly
 370 375 380

atc cac cag cgg gct atc tgc gtt tat ggg gct ggg gac ttg aat tgg 1200
 Ile His Gln Arg Ala Ile Cys Val Tyr Gly Ala Gly Asp Leu Asn Trp
 385 390 395 400

atg ctt caa aac cat cac ctg ttg gcc aac aag ttt gac cca aag gta 1248
 Met Leu Gln Asn His His Leu Leu Ala Asn Lys Phe Asp Pro Lys Val
 405 410 415

gat gat aat gct ctt cag tgc tta gaa gaa tac cta cgt tat aag gcc 1296
 Asp Asp Asn Ala Leu Gln Cys Leu Glu Glu Tyr Leu Arg Tyr Lys Ala
 420 425 430

atc tat ggg act gaa ctt tga 1317
 Ile Tyr Gly Thr Glu Leu
 435

<210> 15
 <211> 438
 <212> PRT
 <213> Homo sapiens

<400> 15
 Met Val Gln Trp Lys Arg Leu Cys Gln Leu His Tyr Leu Trp Ala Leu
 1 5 10 15

Gly Cys Tyr Met Leu Leu Ala Thr Val Ala Leu Lys Leu Ser Phe Arg
 20 25 30

Leu Lys Cys Asp Ser Asp His Leu Gly Leu Glu Ser Arg Glu Ser Gln
 35 40 45

Ser Gln Tyr Cys Arg Asn Ile Leu Tyr Asn Phe Leu Lys Leu Pro Ala
 50 55 60

Lys Arg Ser Ile Asn Cys Ser Gly Val Thr Arg Gly Asp Gln Glu Ala
 65 70 75 80

Val Leu Gln Ala Ile Leu Asn Asn Leu Glu Val Lys Lys Lys Arg Glu
 85 90 95

Pro Phe Thr Asp Thr His Tyr Leu Ser Leu Thr Arg Asp Cys Glu His
 100 105 110

63n

Phe	Lys	Ala	Glu	Arg	Lys	Phe	Ile	Gln	Phe	Pro	Leu	Ser	Lys	Glu	Glu	115	120	125
Val	Glu	Phe	Pro	Ile	Ala	Tyr	Ser	Met	Val	Ile	His	Glu	Lys	Ile	Glu	130	135	140
Asn	Phe	Glu	Arg	Leu	Leu	Arg	Ala	Val	Tyr	Ala	Pro	Gln	Asn	Ile	Tyr	145	150	155
Cys	Val	His	Val	Asp	Glu	Lys	Ser	Pro	Glu	Thr	Phe	Lys	Glu	Ala	Val	165	170	175
Lys	Ala	Ile	Ile	Ser	Cys	Phe	Pro	Asn	Val	Phe	Ile	Ala	Ser	Lys	Leu	180	185	190
Val	Arg	Val	Val	Tyr	Ala	Ser	Trp	Ser	Arg	Val	Gln	Ala	Asp	Leu	Asn	195	200	205
Cys	Met	Glu	Asp	Leu	Leu	Gln	Ser	Ser	Val	Pro	Trp	Lys	Tyr	Phe	Leu	210	215	220
Asn	Thr	Cys	Gly	Thr	Asp	Phe	Pro	Ile	Lys	Ser	Asn	Ala	Glu	Met	Val	225	230	235
Gln	Ala	Leu	Lys	Met	Leu	Asn	Gly	Arg	Asn	Ser	Met	Glu	Ser	Glu	Val	245	250	255
Pro	Pro	Lys	His	Lys	Glu	Thr	Arg	Trp	Lys	Tyr	His	Phe	Glu	Val	Val	260	265	270
Arg	Asp	Thr	Leu	His	Leu	Thr	Asn	Lys	Lys	Lys	Asp	Pro	Pro	Pro	Tyr	275	280	285
Asn	Leu	Thr	Met	Phe	Thr	Gly	Asn	Ala	Tyr	Ile	Val	Ala	Ser	Arg	Asp	290	295	300
Phe	Val	Gln	His	Val	Leu	Lys	Asn	Pro	Lys	Ser	Gln	Gln	Leu	Ile	Glu	305	310	315
Trp	Val	Lys	Asp	Thr	Tyr	Ser	Pro	Asp	Glu	His	Leu	Trp	Ala	Thr	Leu	325	330	335
Gln	Arg	Ala	Arg	Trp	Met	Pro	Gly	Ser	Val	Pro	Asn	His	Pro	Lys	Tyr	340	345	350
Asp	Ile	Ser	Asp	Met	Thr	Ser	Ile	Ala	Arg	Leu	Val	Lys	Trp	Gln	Gly	355	360	365
His	Glu	Gly	Asp	Ile	Asp	Lys	Gly	Ala	Pro	Tyr	Ala	Pro	Cys	Ser	Gly	370	375	380
Ile	His	Gln	Arg	Ala	Ile	Cys	Val	Tyr	Gly	Ala	Gly	Asp	Leu	Asn	Trp	385	390	395
Met	Leu	Gln	Asn	His	His	Leu	Leu	Ala	Asn	Lys	Phe	Asp	Pro	Lys	Val	405	410	415

630

Asp Asp Asn Ala Leu Gln Cys Leu Glu Glu Tyr Leu Arg Tyr Lys Ala
 420 425 430

Ile Tyr Gly Thr Glu Leu
 435

<210> 16

<211> 1203

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1200)

<223> The gene of IGnT

<400> 16

atg cct tta tca atg cgt tac ctc ttc ata att tct gtc tct agt gta 48
 Met Pro Leu Ser Met Arg Tyr Leu Phe Ile Ile Ser Val Ser Ser Val
 1 5 10 15

att att ttt atc gtc ttc tct gtg ttc aat ttt ggg gga gat cca agc 96
 Ile Ile Phe Ile Val Phe Ser Val Phe Asn Phe Gly Gly Asp Pro Ser
 20 25 30

ttc caa agg cta aat atc tca gac cct ttg agg ctg act caa gtt tgc 144
 Phe Gln Arg Leu Asn Ile Ser Asp Pro Leu Arg Leu Thr Gln Val Cys
 35 40 45

aca tct ttt atc aat gga aaa aca cgt ttc ctg tgg aaa aac aaa cta 192
 Thr Ser Phe Ile Asn Gly Lys Thr Arg Phe Leu Trp Lys Asn Lys Leu
 50 55 60

atg atc cat gag aag tct tct tgc aag gaa tac ttg acc cag agc cac 240
 Met Ile His Glu Lys Ser Ser Cys Lys Glu Tyr Leu Thr Gln Ser His
 65 70 75 80

tac atc aca gcc cct tta tct aag gaa gaa gct gac ttt ccc ttg gca 288
 Tyr Ile Thr Ala Pro Leu Ser Lys Glu Glu Ala Asp Phe Pro Leu Ala
 85 90 95

tat ata atg gtc atc cat cat cac ttt gac acc ttt gca agg ctc ttc 336
 Tyr Ile Met Val Ile His His His Phe Asp Thr Phe Ala Arg Leu Phe
 100 105 110

agg gct att tac atg ccc caa aat atc tac tgt gtt cat gtg gat gaa 384
 Arg Ala Ile Tyr Met Pro Gln Asn Ile Tyr Cys Val His Val Asp Glu
 115 120 125

aaa gca aca act gaa ttt aaa gat gcg gta gag caa cta tta agc tgc 432
 Lys Ala Thr Thr Glu Phe Lys Asp Ala Val Glu Gln Leu Leu Ser Cys
 130 135 140

63p

ttc cca aac gct ttt ctg gct tcc aag atg gaa ccc gtt gtc tat gga	480
Phe Pro Asn Ala Phe Leu Ala Ser Lys Met Glu Pro Val Val Tyr Gly	
145 150 155 160	
ggg atc tcc agg ctc cag gct gac ctg aac tgc atc aga gat ctt tct	528
Gly Ile Ser Arg Leu Gln Ala Asp Leu Asn Cys Ile Arg Asp Leu Ser	
165 170 175	
gcc ttc gag gtc tca tgg aag tac gtt atc aac acc tgt ggg caa gac	576
Ala Phe Glu Val Ser Trp Lys Tyr Val Ile Asn Thr Cys Gly Gln Asp	
180 185 190	
ttc ccc ctg aaa acc aac aag gaa ata gtt cag tat ctg aaa gga ttt	624
Phe Pro Leu Lys Thr Asn Lys Glu Ile Val Gln Tyr Leu Lys Gly Phe	
195 200 205	
aaa ggt aaa aat atc acc cca ggg gtg ctg ccc cca gct cat gca att	672
Lys Gly Lys Asn Ile Thr Pro Gly Val Leu Pro Pro Ala His Ala Ile	
210 215 220	
gga cgg act aaa tat gtc cac caa gag cac ctg ggc aaa gag ctt tcc	720
Gly Arg Thr Lys Tyr Val His Gln Glu His Leu Gly Lys Glu Leu Ser	
225 230 235 240	
tat gtg ata aga aca aca gcg ttg aaa ccg cct ccc ccc cat aat ctc	768
Tyr Val Ile Arg Thr Thr Ala Leu Lys Pro Pro Pro Pro His Asn Leu	
245 250 255	
aca att tac ttt ggc tct gcc tat gtg gct cta tca aga gag ttt gcc	816
Thr Ile Tyr Phe Gly Ser Ala Tyr Val Ala Leu Ser Arg Glu Phe Ala	
260 265 270	
aac ttt gtt ctg cat gac cca cgg gct gtt gat ttg ctc cag tgg tcc	864
Asn Phe Val Leu His Asp Pro Arg Ala Val Asp Leu Leu Gln Trp Ser	
275 280 285	
aag gac act ttc agt cct gat gag cat ttc tgg gtg aca ctc aat agg	912
Lys Asp Thr Phe Ser Pro Asp Glu His Phe Trp Val Thr Leu Asn Arg	
290 295 300	
att cca ggt gtt cct ggc tct atg cca aat gca tcc tgg act gga aac	960
Ile Pro Gly Val Pro Gly Ser Met Pro Asn Ala Ser Trp Thr Gly Asn	
305 310 315 320	
ctc aga gct ata aag tgg agt gac atg gaa gac aga cac gga ggc tgc	1008
Leu Arg Ala Ile Lys Trp Ser Asp Met Glu Asp Arg His Gly Gly Cys	
325 330 335	
cac ggc cac tat gta cat ggt att tgt atc tat gga aac gga gac tta	1056
His Gly His Tyr Val His Gly Ile Cys Ile Tyr Gly Asn Gly Asp Leu	
340 345 350	
aag tgg ctg gtt aat tca cca agc ctg ttt gct aac aag ttt gag ctt	1104
Lys Trp Leu Val Asn Ser Pro Ser Leu Phe Ala Asn Lys Phe Glu Leu	
355 360 365	

63q

aat acc tac ccc ctt act gtg gaa tgc cta gaa ctg agg cat cgc gaa 1152
 Asn Thr Tyr Pro Leu Thr Val Glu Cys Leu Glu Leu Arg His Arg Glu
 370 375 380

aga acc ctc aat cag agt gaa act gcg ata caa ccc agc tgg tat ttt 1200
 Arg Thr Leu Asn Gln Ser Glu Thr Ala Ile Gln Pro Ser Trp Tyr Phe
 385 390 395 400

tga 1203

<210> 17
 <211> 400
 <212> PRT
 <213> Homo sapiens

<400> 17
 Met Pro Leu Ser Met Arg Tyr Leu Phe Ile Ile Ser Val Ser Ser Val
 1 5 10 15

Ile Ile Phe Ile Val Phe Ser Val Phe Asn Phe Gly Gly Asp Pro Ser
 20 25 30

Phe Gln Arg Leu Asn Ile Ser Asp Pro Leu Arg Leu Thr Gln Val Cys
 35 40 45

Thr Ser Phe Ile Asn Gly Lys Thr Arg Phe Leu Trp Lys Asn Lys Leu
 50 55 60

Met Ile His Glu Lys Ser Ser Cys Lys Glu Tyr Leu Thr Gln Ser His
 65 70 75 80

Tyr Ile Thr Ala Pro Leu Ser Lys Glu Glu Ala Asp Phe Pro Leu Ala
 85 90 95

Tyr Ile Met Val Ile His His His Phe Asp Thr Phe Ala Arg Leu Phe
 100 105 110

Arg Ala Ile Tyr Met Pro Gln Asn Ile Tyr Cys Val His Val Asp Glu
 115 120 125

Lys Ala Thr Thr Glu Phe Lys Asp Ala Val Glu Gln Leu Leu Ser Cys
 130 135 140

Phe Pro Asn Ala Phe Leu Ala Ser Lys Met Glu Pro Val Val Tyr Gly
 145 150 155 160

Gly Ile Ser Arg Leu Gln Ala Asp Leu Asn Cys Ile Arg Asp Leu Ser
 165 170 175

Ala Phe Glu Val Ser Trp Lys Tyr Val Ile Asn Thr Cys Gly Gln Asp
 180 185 190

Phe Pro Leu Lys Thr Asn Lys Glu Ile Val Gln Tyr Leu Lys Gly Phe
 195 200 205

63r

Lys	Gly	Lys	Asn	Ile	Thr	Pro	Gly	Val	Leu	Pro	Pro	Ala	His	Ala	Ile	210	215	220	
Gly	Arg	Thr	Lys	Tyr	Val	His	Gln	Glu	His	Leu	Gly	Lys	Glu	Leu	Ser	225	230	235	240
Tyr	Val	Ile	Arg	Thr	Thr	Ala	Leu	Lys	Pro	Pro	Pro	Pro	His	Asn	Leu	245	250	255	
Thr	Ile	Tyr	Phe	Gly	Ser	Ala	Tyr	Val	Ala	Leu	Ser	Arg	Glu	Phe	Ala	260	265	270	
Asn	Phe	Val	Leu	His	Asp	Pro	Arg	Ala	Val	Asp	Leu	Leu	Gln	Trp	Ser	275	280	285	
Lys	Asp	Thr	Phe	Ser	Pro	Asp	Glu	His	Phe	Trp	Val	Thr	Leu	Asn	Arg	290	295	300	
Ile	Pro	Gly	Val	Pro	Gly	Ser	Met	Pro	Asn	Ala	Ser	Trp	Thr	Gly	Asn	305	310	315	320
Leu	Arg	Ala	Ile	Lys	Trp	Ser	Asp	Met	Glu	Asp	Arg	His	Gly	Gly	Cys	325	330	335	
His	Gly	His	Tyr	Val	His	Gly	Ile	Cys	Ile	Tyr	Gly	Asn	Gly	Asp	Leu	340	345	350	
Lys	Trp	Leu	Val	Asn	Ser	Pro	Ser	Leu	Phe	Ala	Asn	Lys	Phe	Glu	Leu	355	360	365	
Asn	Thr	Tyr	Pro	Leu	Thr	Val	Glu	Cys	Leu	Glu	Leu	Arg	His	Arg	Glu	370	375	380	
Arg	Thr	Leu	Asn	Gln	Ser	Glu	Thr	Ala	Ile	Gln	Pro	Ser	Trp	Tyr	Phe	385	390	395	400

CLAIMS:

1. An isolated nucleic acid encoding a UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase (termed C2GnT3) having glycosyltransferase activity or a fragment thereof having glycosyltransferase activity, and an amino acid sequence at least 70 % identical to SEQ ID NO:2.
2. The isolated nucleic acid of claim 1 wherein said C2GnT3 comprises the amino acid sequence of residues 39-453 of SEQ ID NO:2 or a function-conservative variant thereof having an amino acid sequence at least 70 % identical to residues 39-453 of SEQ ID NO:2.
3. The isolated nucleic acid of claim 1 or 2, wherein said nucleic acid is DNA.
4. The isolated nucleic acid of claim 3, wherein said DNA is cDNA or genomic DNA.
5. An isolated nucleic acid encoding an active UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase that hybridizes under conditions of high stringency with a nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 1, said stringency being no less than 0.5xSSC at 65°C.
6. A nucleic acid vector comprising a nucleic acid according to any one of claims 1-5.
7. A vector as defined in claim 6, wherein the nucleic acid encoding C2GnT3 is operably linked to a transcriptional regulatory element.

8. A cell comprising a vector as defined in claim 6 or 7.

9. A cell as defined in claim 8, wherein said cell is stably transfected with said vector.

10. A cell as defined in claim 8 or 9, wherein said cell produces enzymatically active C2GnT3.

11. A cell as defined in any one of claims 8-10, wherein said cell is selected from the group consisting of bacterial, yeast, insect, avian, and mammalian cells.

12. A cell as defined in claim 11, wherein said cell is Sf9.

13. A cell as defined in claim 11, wherein said cell is CHO.

14. A method for producing an active UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase, which method comprises:

- (i) introducing into a host cell an isolated nucleic acid according to any one of claims 1-5, or a DNA construct comprising said nucleic acid;
- (ii) growing the host cell under conditions suitable for human UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase expression; and
- (iii) isolating the UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase thereof produced by the host cell.

15. An isolated UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase (C2GnT3) polypeptide, a function-conservative variant thereof, or a fragment thereof having glycosyltransferase activity, wherein said C2GnT3 polypeptide, variant or fragment comprises an amino acid sequence that is at least 70 % identical to SEQ ID NO:2.

16. An isolated C2GnT3 polypeptide of claim 15 comprising the amino acid sequence of residues 39-453 of SEQ ID NO:2, or a function-conservative variant thereof having an amino acid sequence at least 70 % identical to residues 39-453 of SEQ ID NO:2.

17. An isolated polypeptide of claim 15 comprising the amino acid sequence of SEQ ID NO:2.

18. An isolated C2GnT3 polypeptide or a function-conservative variant thereof of any one of claims 15 to 17, which is a fusion polypeptide fused in frame to a second sequence, wherein said second sequence comprises an affinity ligand or a reactive group.

19. A method of screening one or more agents for the ability to inhibit or stimulate UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase activity in a cell-free or cell-based assay, which comprises:

- (i) contacting a polypeptide according to any one of claims 15-18, or produced by the method of claim 14, or a cell according to any one of claims 8-13 that recombinantly expresses said polypeptide, with

- agents selected from the group consisting of compounds, compositions, antibodies and antibody fragments, antisense sequences and ribozyme nucleotide sequences for said polypeptide under assay conditions suitable for the detection of said enzymatic activity; and
- (ii) measuring whether said enzymatic activity is thereby inhibited or stimulated by one or more agents.

20. A method for the identification of DNA sequence variations from the C2GnT3 gene as defined in claims 1-5, comprising the steps of:

- (i) isolating DNA from a biological sample;
- (ii) amplifying C2GnT3 genomic regions by PCR; and
- (iii) detecting the presence of DNA sequence variation by DNA sequencing, single-strand conformational polymorphism (SSCP) or mismatch mutation.

21. An antibody being specific for C2GnT3 as claimed in claim 17.

22. A probe comprising a sequence encoding a polypeptide as claimed in any one of claims 15-17 or a part thereof comprising at least 15-50 nucleotides.

23. A method of diagnosing and monitoring conditions mediated by a C2GnT3 polypeptide as claimed in any one of claims 15 to 17 in an individual, wherein said condition is a thymus-related disorder selected from the group consisting of a thymus tumour, thymus cancer, thymus hypoactivity, thymus hyperactivity, thymus atrophy, and thymus enlargement, comprising determining the presence

in a biological sample from the individual of a nucleic acid molecule as claimed in any one of claims 1-5 or a polypeptide as claimed in any one of claims 15-17.

24. A method for identifying a substance that associates with a polypeptide as claimed in any one of claims 15-18 comprising:

- (i) reacting the polypeptide with at least one substance which potentially can associate with the polypeptide, under conditions which permit the association between the substance and polypeptide; and
- (ii) removing or detecting polypeptide associated with the substance, wherein detection of associated polypeptide and substance indicates that the substance associates with the polypeptide.

25. A method of evaluating a compound for its ability to modulate the biological activity of a polypeptide as claimed in any one of claims 15-18 comprising providing a known concentration of the polypeptide with a substance which associates with the polypeptide, and a test compound under conditions which permit the formation of complexes between the substance and polypeptide, and removing and/or detecting complexes.

26. A method of detecting a nucleic acid molecule encoding a UDP-N-acetylglucosamine: galactose- β 1,3-N-acetylgalactosamine- α -R β 1,6-N-acetylglucosaminyltransferase (C2GnT3) polypeptide in a biological sample comprising the steps of:

- (i) hybridizing the nucleic acid of any one of claims 1-5, or the probe of claim 22, to nucleic acid of the biological sample, thereby forming a hybridization complex;
- (ii) detecting the hybridization complex;

wherein the presence of the hybridization complex correlates with the presence of a nucleic acid molecule encoding the polypeptide in the biological sample.

27. A method according to claim 26 wherein nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.

28. A composition comprising one or more of a nucleic acid as claimed in any one of claims 1-7 or a polypeptide as claimed in any one of claims 15-18, and a pharmaceutically acceptable vehicle for use as a medicament.

29. A composition comprising an antibody according to claim 21, and a pharmaceutically acceptable vehicle for use as a medicament, for the treatment of a thymus-related disorder selected from the group consisting of a thymus tumour, thymus cancer, thymus hypoactivity, thymus hyperactivity, thymus atrophy, and thymus enlargement.

30. The use of one or more nucleic acid as claimed in any one of claims 1-7 or a polypeptide as claimed in any one of claims 15-18 for the manufacture of a medicament for the treatment of a thymus-related disorder selected from the group consisting of a thymus tumour, thymus cancer, thymus hypoactivity, thymus hyperactivity, thymus atrophy, and thymus enlargement.


31. The use of an antibody according to claim 21 for the manufacture of a medicament for the treatment of a thymus-related disorder selected from the group consisting of a thymus tumour, thymus cancer, thymus hypoactivity, thymus hyperactivity, thymus atrophy, and thymus enlargement.


32. A method for preparing an oligosaccharide comprising contacting a reaction mixture comprising an activated GlcNAc and an acceptor with an enzymatically active polypeptide as claimed in any one of claims 15-18.

1/5

Fig.1


Fig. 2






4/5

Fig. 4



C2GnT3



TSHC123: 5'-GGGCAGCATTGGCCTAGTATG-3'

TSHC119: 5'-GATCTCTGATTGGCTCAGTG-3'

Fig. 5